Author: "F. Anaya" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"F. Anaya"' showing total 265 results

Start Over Author "F. Anaya"

265 results on '"F. Anaya"'

1. PCR utility over conventional tests for detection of Mycobacterium spp. in patients with mastitis and granulomatous lymphadenitis: Case series

Author: José J. Márquez-Barajas, Manuel Solano-Genesta, Leonora Valdez-Rojas, Johana J. Garnica-Vázquez, José F. Anaya-Gómez, Sergio A. Trujillo-Vega, Oscar Bañuelos-Robles, Guillermo E. Juárez-López, Estefania N. Valdés-Peregrina, Cristina A. Luna-González, and Luis A. García-González
Subjects: Quantitative polymerase chain reaction. Mycobacterium spp. Granulomatous mastitis. Granulomatous lymphadenitis., Medicine (General), R5-920
Abstract: Objective: The present study aims to highlight the utility of quantitative polymerase chain reaction (qPCR) as a method for identifying typical and atypical mycobacterial infections in patients with mastitis and granulomatous lymphadenitis. Materials and methods: A total of five patients initially diagnosed with mastitis or granulomatous lymphadenitis based on their clinical characteristics in whom conventional tests were used as a diagnostic method were selected. Conclusion: The present study showed that the routine performance of qPCR for typical and atypical mycobacteria allows for improved diagnosis.
Published: 2021
Full Text: View/download PDF

2. Salicylic Acid and Iron Reduce Salt-Induced Oxidative Stress and Photosynthesis Inhibition in Strawberry Plants

Author: K. Lamnai, F. Anaya, R. Fghire, I. Janah, S. Wahbi, and K. Loutfi
Subjects: Plant Science
Published: 2022

3. COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain

Author: Marian Goicoechea, Antonia Mijaylova, Manuel Rengel, Eduardo Verde, Adriana Acosta, Alberto Tejedor, David Arroyo, Arturo Bascuñana, Javier Carbayo, Ana Pérez de José, Daniel Barraca, José Luño, Ángela González Rojas, Ana María García Prieto, Soraya Abad, Andrés Delgado, Nicolás Macías, F. Anaya, Luis Alberto Sánchez Cámara, Diego Barbieri, María Luisa Rodríguez Ferrero, Alejandra Muñoz de Morales, Patrocinio Rodríguez Benítez, Rosa Melero, Almudena Vega, Ursula Verdalles, and Inés Aragoncillo
Subjects: Male, 0301 basic medicine, medicine.medical_treatment, 030232 urology & nephrology, Azithromycin, Lopinavir, 0302 clinical medicine, Oxygen therapy, Hospital Mortality, Aged, 80 and over, education.field_of_study, Clinical course, Middle Aged, Prognosis, Anti-Bacterial Agents, Drug Combinations, Nephrology, Hemodialysis, Female, Coronavirus Infections, Hydroxychloroquine, Adult, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Pneumonia, Viral, Population, Article, Antimalarials, 03 medical and health sciences, Renal Dialysis, Internal medicine, medicine, Humans, education, Pandemics, Dialysis, Aged, Retrospective Studies, Ritonavir, SARS-CoV-2, business.industry, COVID-19, Retrospective cohort study, medicine.disease, mortality, Coronavirus, Pneumonia, 030104 developmental biology, Spain, Kidney Failure, Chronic, business
Abstract: SARS-CoV-2-pneumonia emerged in Wuhan, China in December 2019. Unfortunately, there is lack of evidence about the optimal management of novel coronavirus disease 2019 (COVID-19), even less in patients on maintenance hemodialysis (MHD) therapy than in the general population. In this retrospective observational single-center study we analyzed the clinical course and outcomes of all MHD patients hospitalized with COVID-19 from March 12th to April 10th, 2020 as confirmed by real time polymerase chain reaction. Baseline features, clinical course, laboratory data, and different therapies were compared between survivors and non-survivors to identify risk factors associated with mortality. Among the 36 patients, 11 (30.5%) died and 7 could be discharged within the observation period. Clinical and radiological evolution during the first week of admission were predictive of mortality. Among the 36 patients, 18 had worsening of their clinical status, as defined by severe hypoxia with oxygen therapy requirements greater than 4 Liters/minute and radiological worsening. Significantly 11 out of those 18 patients (61.1%) died. None of the classical cardiovascular risk factors in the general population were associated with higher mortality. However, a longer time on hemodialysis (hazard ratio 1.008(95% confidence interval 1.001-1.015) per year), increased LDH levels (1.006(1.001-1.011), and lower lymphocyte count (0.996 (0.992-1.000) one week after clinical onset were all significantly associated with higher mortality risk. Thus, the mortality among hospitalized hemodialysis patients diagnosed with COVID-19 is high. Lymphopenia and increased LDH levels were associated with poor prognosis., Graphical abstract
Published: 2020

4. Efficacy of Evolocumab vs low‐density lipoprotein cholesterol apheresis in patients with familial hypercholesterolemia and high cardiovascular risk (EVOLAFER01)

Author: Nicolás Macías, Esther Torres, Marian Goicoechea, F. Anaya, Andrés Hernández, María Luisa Rodríguez Ferrero, and Ana Isabel Morales García
Subjects: Male, medicine.medical_specialty, Familial hypercholesterolemia, 030204 cardiovascular system & hematology, Antibodies, Monoclonal, Humanized, Gastroenterology, Hyperlipoproteinemia Type II, 03 medical and health sciences, 0302 clinical medicine, Refractory, Risk Factors, Internal medicine, Hyperlipidemia, medicine, Clinical endpoint, Humans, Adverse effect, Aged, Inflammation, biology, business.industry, Anticholesteremic Agents, Antibodies, Monoclonal, Cholesterol, LDL, Hematology, General Medicine, Lipoprotein(a), Middle Aged, medicine.disease, Lipids, Evolocumab, Cardiovascular Diseases, Blood Component Removal, biology.protein, Female, lipids (amino acids, peptides, and proteins), business, 030215 immunology, Lipoprotein
Abstract: Low-density lipoprotein (LDL) apheresis has been considered the last option to treat refractory hyperlipidemia in patients with familiar hypercholesterolemia (FH). Evolocumab is a monoclonal antibody which has shown significant reduction of low-density lipoprotein cholesterol (LDL-C) serum levels and cardiovascular events. The aim of the study was to examine the comparative impact of LDL-apheresis vs Evolocumab vs the combination of both LDL-apheresis and Evolocumab on lipid and lipoprotein parameters, and other metabolic/inflammatory measures. DESIGN OF THE STUDY Non-randomized open case series study of 10 adult patients diagnosed with FH already on long-term LDL-apheresis therapy. The study was developed in three consecutive phases to compare LDL-apheresis, Evolocumab treatment and the combination of both. Laboratory parameters were collected pre and post LDL-apheresis and before Evolocumab administration. The primary endpoint was the reduction of LDL-C during the three phases. RESULTS Reduction of LDL-C levels with Evolocumab were 31.4% vs LDL-apheresis from 153 ± 35 mg/dL to 105 ± 56 mg/dL (P
Published: 2019

5. Valganciclovir—Ganciclovir Use and Systematic Therapeutic Drug Monitoring. An Invitation to Antiviral Stewardship

Author: Pilar Catalán, Maria Luisa Rodríguez-Ferrero, Alicia Galar, Xandra García-González, Emilio Bouza, Iago Sousa-Casasnovas, F. Anaya, Ana Fernández-Cruz, Eduardo Zatarain, Almudena Burillo, Patricia Muñoz, and Maricela Valerio
Subjects: 0301 basic medicine, Microbiology (medical), Ganciclovir, medicine.medical_specialty, Drug discontinuation, ganciclovir, Farmacología, viruses, therapeutic drug monitoring, 030106 microbiology, Inmunología, valganciclovir, Renal function, 030226 pharmacology & pharmacy, Biochemistry, Microbiology, Article, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Medicine, Pharmacology (medical), Hematología, Dosing, General Pharmacology, Toxicology and Pharmaceutics, Prospective cohort study, medicine.diagnostic_test, business.industry, lcsh:RM1-950, Valganciclovir, serum levels, lcsh:Therapeutics. Pharmacology, Infectious Diseases, Therapeutic drug monitoring, Toxicity, business, CMV infection, medicine.drug
Abstract: Valganciclovir (VGCV) and ganciclovir (GCV) doses must be adjusted according to indication, renal function and weight. No specific therapeutic exposure values have been established. We aimed to evaluate the adequacy of VGCV/GCV doses, to assess the interpatient variability in GCV serum levels, to identify predictive factors for this variability and to assess the clinical impact. This is a prospective study at a tertiary institution including hospitalized patients receiving VGCV/GCV prophylaxis or treatment. Adequacy of the antiviral dose was defined according to cytomegalovirus guidelines. Serum levels were determined using High-Performance Liquid Chromatography. Blood samples were drawn at least 3 days after antiviral initiation. Outcome was considered favorable if there was no evidence of cytomegalovirus infection during prophylaxis or when a clinical and microbiological resolution was attained within 21 days of treatment and no need for drug discontinuation due to toxicity. Seventy consecutive patients [74.3% male/median age: 59.2 years] were included. VGCV was used in 25 patients (35.7%) and GCV in 45 (64.3%). VGCV/GCV initial dosage was deemed adequate in 47/70 cases (67.1%), lower than recommended in 7/70 (10%) and higher in 16/70 (22.9%). Large inter-individual variability of serum levels was observed, with median trough levels of 2.3 mg/L and median peak levels of 7.8 mg/L. Inadequate dosing of VGCV/GCV and peak levels lower than 8.37 or greater than 11.86 mg/L were related to poor outcome. Further studies must be performed to confirm these results and to conclusively establish if VGCV/GCV therapeutic drug monitoring could be useful to improve outcomes in specific clinical situations.
Published: 2021
Full Text: View/download PDF

6. Renal long-term outcome of critically ill COVID-19 patients with acute kidney failure and continuous renal replacement therapy

Author: F. Anaya, María Olmedo, Nicolás Macías, Almudena Vega, Alejandra Muñoz de Morales, Patrocinio Rodriguez-Benitez, Eduardo Verde, Arturo Bascuñana, Ana Pérez de José, Marian Goicoechea, David Arroyo, Ana García-Prieto, Patricia Piñero, Jamil Cedeño, Ángela González-Rojas, Ursula Verdalles, Soraya Abad, Inés Aragoncillo, Daniel Barraca, Rosa Melero, Luis Sanchez-Cámara, Maria Luisa Rodríguez-Ferrero, Javier Carbayo, Adriana Acosta, Manuel Rengel, and Antonia Mijaylova
Subjects: Transplantation, 2019-20 coronavirus outbreak, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), business.industry, Critically ill, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), medicine.medical_treatment, Acute kidney failure, MEDLINE, medicine.disease, Nephrology, Medicine, Renal replacement therapy, AcademicSubjects/MED00340, business, Intensive care medicine, Letter to the Editor
Published: 2021

7. Secondary antibody deficiency is associated with development of infection in kidney transplantation: Results of a multicenter study

Author: Marisa Rodriguez-Ferrero, Sergio Mezzano, M. Jaramillo, Manuel Arias, Manel Perelló, F. Anaya, Daniel Seron, Joaquin Luis Navarro, Javier Carbone, Emilio Rodrigo, Elizabeth Sarmiento, Patricia Muñoz, Marisa di Natale, I. Ezzahouri, Alba Alarcon, L. Calahorra, Boris Karanovic, Maricela Jimenez, and Marcos López-Hoyos
Subjects: Adult, medicine.medical_specialty, Congenital cytomegalovirus infection, Cytomegalovirus, 030230 surgery, Gastroenterology, Immunoglobulin G, Hypogammaglobulinemia, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Medicine, Humans, Prospective Studies, Kidney transplantation, Transplantation, biology, business.industry, Antibody titer, Odds ratio, medicine.disease, Kidney Transplantation, Infectious Diseases, Cytomegalovirus Infections, biology.protein, 030211 gastroenterology & hepatology, Antibody, business
Abstract: BACKGROUND We performed a multicenter study to assess the association between secondary antibody deficiency (immunoglobulin G [IgG] hypogammaglobulinemia combined with low levels of specific antibodies) and development of infection in kidney transplantation. METHODS We prospectively analyzed 250 adult kidney recipients at four centers. The assessment points were before transplantation and 7 and 30 days after transplantation. The immune parameters were as follows: IgG, IgA, and IgM and complement factors C3 and C4 tested by nephelometry; specific IgG antibodies to cytomegalovirus (CMV) and IgG and IgG2 antibodies to pneumococcal polysaccharide (anti-PPS) determined using enzyme-linked immunosorbent assay. The clinical follow-up period lasted 6 months. The clinical outcomes were CMV disease and recurrent bacterial infections requiring antimicrobial therapy. STATISTICS Multivariate logistic regression. RESULTS At day 7, IgG hypogammaglobulinemia (IgG levels
Published: 2020

8. SP813INFLUENCE OF CYTOCHROME P450 3A5 (CYP3A5) GENTEIC POLYMORPHISM ON SHORT-TERM OUTCOMES IN KIDNEY TRANSPLANT RECIPIENTS TREATED WITH TACROLIMUS

Author: F. Anaya, Tania Linares, Alba Santos, Nicolás Macías, Esther Torres, Ana García-Prieto, Rodriguez Marisa, Luis Sanchez-Cámara, and Esther Hurtado
Subjects: Transplantation, medicine.medical_specialty, Nephrology, business.industry, Internal medicine, medicine, business, CYP3A5, Kidney transplant, Gastroenterology, Tacrolimus
Published: 2017

9. IgG Hypogammaglobulinemia is a Risk Factor of Cytomegalovirus Infection in a Multicenter Study in Kidney Transplantation

Author: Elizabeth Sarmiento, Roberto Alonso, Patricia Muñoz, Javier Carbone, Pilar Catalán, Joaquin Luis Navarro, Maria Luisa Rodríguez-Ferrero, Boris Karanovic, F. Anaya, Alia Eworo, Marcos López-Hoyos, Manuel Arias, and Emilio Rodrigo
Subjects: Transplantation, medicine.medical_specialty, business.industry, 030230 surgery, medicine.disease, Gastroenterology, Hypogammaglobulinemia, Cytomegalovirus infection, 03 medical and health sciences, 0302 clinical medicine, Multicenter study, Internal medicine, medicine, 030211 gastroenterology & hepatology, Risk factor, business, Kidney transplantation
Published: 2018

10. Intravenous Immunoglobulin Replacement Therapy in Solid Organ Transplantation with Severe Infections and Secondary Antibody Deficiency

Author: Elizabeth Sarmiento, Maricela Valerio, F. Anaya, Judith Montanchez, Magdalena Salcedo, Patricia Muñoz, Joaquin Luis Navarro, Eduardo Zatarain, Ainhoa Fernandez, Juan Fernández-Yáñez, Javier Carbone, and Maria Luisa Rodríguez-Ferrero
Subjects: Transplantation, biology, business.industry, 030230 surgery, 03 medical and health sciences, 0302 clinical medicine, Immunology, biology.protein, Secondary antibody deficiency, Medicine, 030211 gastroenterology & hepatology, Antibody, Solid organ transplantation, business
Published: 2018

11. Different Patterns of Risk Factors for Mortality according Recipient Age after Renal Transplantation. A Multicenter and Prospective Study at Ten Years in the Clinical Practice

Author: Luis M Pallardó, Roberto Marcén, Francisco Valdés, Fernando Escuin, Javier Gainza, José M. Morales, Miguel Gonzalez Molina, Jesus Bustamante, Domingo Del Castillo, Daniel Serón, Manuel Arias, Mercedes Cabello, F. Anaya, Salvador Gil Vernet, Federico Oppenheimer, and Amado Andrés
Subjects: Clinical Practice, Transplantation, Pediatrics, medicine.medical_specialty, business.industry, Medicine, business, Prospective cohort study
Published: 2018

12. Donor Specific Antibodies after Conversion from Mycophenolate Mofetil with Standard Exposure Tacrolimus to Everolimus with Tacrolimus Minimization in Stable Kidney Transplanted Recipients

Author: Antonio Balas, Jose L. Vicario, Esther Hurtado, F. Anaya, Raquel Alenda, Maira Luisa Rodríguez-Ferrero, and Félix García-Sánchez
Subjects: Transplantation, Kidney, medicine.medical_specialty, medicine.anatomical_structure, Everolimus, business.industry, Donor specific antibodies, Urology, Medicine, business, Mycophenolate, Tacrolimus, medicine.drug
Published: 2018

13. Early statin use is an independent predictor of long-term graft survival

Author: Jaime Sánchez-Plumed, Carlos Jiménez, Daniel Serón, Julio Pascual, Domingo Del Castillo, Francesc Moreso, N. Calvo, and F. Anaya
Subjects: Transplantation, medicine.medical_specialty, business.industry, Proportional hazards model, graft failure, renal transplantation, Lower risk, Confidence interval, statins, Surgery, surgical procedures, operative, Pharmacotherapy, Nephrology, Relative risk, Internal medicine, Propensity score matching, Cohort, medicine, Original Article, business
Abstract: Background. Statin use in renal transplantation has been associated with a lower risk of patient death but not with an improvement of graft functional survival. The aim of this study is to evaluate the effect of statin use in graft survival, death-censored graft survival and patient survival using the data recorded on the Spanish Late Allograft Dysfunction Study Group. Patients and methods. Patients receiving a renal allograft in Spain in 1990, 1994, 1998 and 2002 were considered. Since the mean follow-up in the 2002 cohort was 3 years, statin use was analysed considering its introduction during the first year or during the initial 2 years after transplantation. Univariate and multivariate Cox regression analyses with a propensity score for statin use were employed to analyse graft survival, death-censored graft survival and patient survival. Results. In the 4682 evaluated patients, the early statin use after transplantation significantly increased from 1990 to 2002 (12.7%, 27.9%, 47.7% and 53.0%, P < 0.001). Statin use during the first year was not associated with graft or patient survival. Statin use during the initial 2 years was associated with a lower risk of graft failure (relative risk [RR] = 0.741 and 95% confidence interval [CI] = 0.635– 0.866, P < 0.001) and patient death (RR = 0.806 and 95% CI = 0.656–0.989, P = 0.039). Death-censored graft survival was not associated with statin use during the initial 2 years. Conclusion. The early introduction of statin treatment after transplantation is associated with a significant decrease in late graft failure due to a risk reduction in patient death.
Published: 2010

14. Partial Recovery of Late Renal Allograft Infarction

Author: L. Bucalo, F. Anaya, Ml. Rodriguez-Ferrrero, A. Santos, and B. Quiroga
Subjects: medicine.medical_specialty, business.industry, Infarction, medicine.disease, Surgery, Thrombotic occlusion, Internal medicine, medicine, Cardiology, Renal allograft, Native kidney, Systemic anticoagulation, Complication, business
Abstract: Late thrombotic occlusion is a rare complication in transplant receipts. If produced immediately posttrasplantation, the treatment includes transplantectomy. However when it occurs later, as in native kidney infarction, this exceptional situation must be treated with systemic anticoagulation and avoiding the underlying condition. We present the first case of a late allograft infarction with partial recovery after systemic anticoagulation.
Published: 2013

15. Health-Related Quality of Life of Patients Receiving Low-toxicity Immunosuppressive Regimens: A Substudy of the Symphony Study

Author: F. Anaya, Federico Oppenheimer, M. Gonzalez-Molina, Jaime Sánchez-Plumed, Domingo Hernández, Francisco B. Ortega, Josep M. Grinyó, Henrik Ekberg, and Pablo Rebollo
Subjects: Adult, Male, medicine.medical_specialty, Daclizumab, Time Factors, Health Status, medicine.medical_treatment, Antibodies, Monoclonal, Humanized, chemistry.chemical_compound, Quality of life, Adrenal Cortex Hormones, Internal medicine, medicine, Humans, Health related quality of life, Transplantation, Creatinine, Dose-Response Relationship, Drug, business.industry, Antibodies, Monoclonal, Immunosuppression, Middle Aged, Mycophenolic Acid, Health Surveys, Kidney Transplantation, Tacrolimus, Surgery, chemistry, Immunoglobulin G, Sirolimus, Toxicity, Cyclosporine, Quality of Life, Female, business, Immunosuppressive Agents, Follow-Up Studies, medicine.drug
Abstract: Objective. To evaluate health-related quality of life (HRQoL) in patients with different low-toxicity regimens post-transplantation. Methods. One hundred fifty-six patients were randomized to standard-dose cyclosporine A (CsA), mycophenolate mofetil, and corticosteroids or daclizumab induction, mycophenolate mofetil, and corticosteroids with a low dose of CsA, tacrolimus (Low-Tac), or sirolimus. SF-36 Health survey was completed at baseline, 3, 6, and 12 months. Results. There were no differences between groups in SF-36 at baseline or at month 12. Low-Tac showed higher scores at month 3 than standard-dose CsA and low dose of CsA. Patients with serum creatinine less than or equal to 1.5 mg/mL had better HRQoL at 6 and 12 months. Proportion of these patients was higher in Low-Tac at 6 months. Physical component summary of Patients increased during follow-up, but mental component summary did not. Patients with acute rejection showed lower mental component summary at 6 months. Conclusions. No HRQoL differences were identified among groups, but the low-dose Tac group showed the fastest improvement. (Less)
Published: 2009

16. Síndrome de Peutz-Jeghers

Author: F. Anaya Barea, E. Galiano Fernández, M.aJ. Pérez Rodríguez, D. de Diego Sierra, and I. Condado Sánchez-Rojas
Subjects: congenital, hereditary, and neonatal diseases and abnormalities, Gastrointestinal tract, medicine.medical_specialty, Peutz-Jeghers syndrome, business.industry, Incidence (epidemiology), Malignization, Mucocutaneous zone, Cancer, Peutz–Jeghers syndrome, medicine.disease, Dermatology, Pediatrics, RJ1-570, Gastrointestinal polyposis, Hamartomatous Polyp, Pediatrics, Perinatology and Child Health, medicine, Lentiginosis, business, Pigmentation disorder
Abstract: El síndrome de Peutz-Jeghers es un raro proceso hereditario que suele iniciarse en la infancia. Se caracteriza por la presencia de lesiones cutáneas pigmentadas y pólipos gastrointestinales. Numerosos estudios revelan una incidencia elevada de cáncer (gastrointestinal y extradigestivo) en estos enfermos y su aparición a temprana edad, así como su asociación con tumores ováricos y testiculares. Por ello, es necesario un estrecho seguimiento y un tratamiento agresivo de estos enfermos.Presentamos 2 hermanos afectados de síndrome de Peutz-Jeghers cuyo padre y abuelo fallecieron a consecuencia de cáncer digestivo relacionado con la enfermedad. : Peutz-Jeghers syndrome is an inherited disorder which usually debuts during childhood. It is characterized by mucocutaneous pigmentation and hamartomatous polyps in the gastrointestinal tract. Numerous reports indicate a high incidence of gastrointestinal and extraintestinal cancer in these patients, their appearance at a young age, as well as its association with ovarian and testicular tumors. An aggresive approach of these patients seems to be necesary.We report the case of two brothers suffering from Peutz-Jeghers syndrome whose father and grandfather died as a consecuence of the progression of an intestinal cancer related to the syndrome.
Published: 2008

17. Influenza vaccination during the first 6 months after solid organ transplantation is efficacious and safe

Author: Patricia Muñoz, J.L. Montero, M.A. Gentil-Govantes, Diego Rincón, José María Aguado, Jordi Carratalà, P. Diez, Julián Torre-Cisneros, Marino Blanes, Angel Bulnes-Ramos, Joan Gavaldà, Manuel Rodríguez, S. Fernández-Rozas, C. Berasategui, I. Morales-Barroso, R. Durán, M.C. Fariñas, Paula López-Roa, Marta Bodro, F. Anaya, Cristina Roca, Elisa Vidal, Magda Campins, A. Gasch, Manuel López-Meseguer, F. Zurbano-Goñi, Miguel Montejo, M. Cobo-Beláustegy, Magdalena Salcedo, Alia Eworo, Elisa Cordero, S. Oriol, J. Fortún, Sylvana Melo dos Santos, M. Valerio, A. Rodríguez, C. Rosso, Francisco López-Medrano, Pilar Pérez-Romero, Rosario Lara, Julia Origüen, Juliana Martinez-Atienza, M.L. Agüera, Jordi Niubó, Emilio Bouza, Martha Kestler, E. Fábrega-García, Josune Goikoetxea, Teresa Aydillo, A. Páez, J.M. Alamo, Fernando Casafont, Sara Cantisán, M. Peghin, N. Sabé, M. A. Marcos, E. Lage, Claudia González-Rico, Y. Sousa, F.J. Molina-Ortega, J.L. Barranco, G. Sanclemente, N. Diez, A. Moreno, M. Sánchez, Pilar Catalán, Berta Sáez, J.M. Arizón, and Alejandro Suárez-Benjumea
Subjects: Adult, Microbiology (medical), medicine.medical_specialty, Adolescent, Drug-Related Side Effects and Adverse Reactions, Influenza vaccine, Disease, Antibodies, Viral, seroprotection, immune response, Young Adult, Influenza A Virus, H1N1 Subtype, Internal medicine, Influenza, Human, medicine, Humans, Prospective Studies, Adverse effect, Prospective cohort study, solid organ transplantation, Immunization Schedule, Aged, Early vaccination, Aged, 80 and over, business.industry, Influenza A Virus, H3N2 Subtype, Immunogenicity, Organ Transplantation, General Medicine, Middle Aged, Transplant Recipients, Confidence interval, Surgery, Vaccination, Transplantation, Influenza B virus, Treatment Outcome, Infectious Diseases, Influenza Vaccines, influenza vaccine, business
Abstract: Preventing influenza infection early after transplantation is essential, given the disease's high mortality. A multicentre prospective cohort study in adult solid organ transplant recipients (SOTR) receiving the influenza vaccine during four consecutive influenza seasons (2009–2013) was performed to assess the immunogenicity and safety of influenza vaccination in SOTR before and 6 months after transplantation. A total of 798 SOTR, 130 of them vaccinated within 6 months of transplantation and 668 of them vaccinated more than 6 months since transplantation. Seroprotection was similar in both groups: 73.1% vs. 76.5% for A/(H1N1)pdm (p 0.49), 67.5% vs. 74.1% for A/H3N2 (p 0.17) and 84.2% vs. 85.2% for influenza B (p 0.80), respectively. Geometric mean titres after vaccination did not differ among groups: 117.32 (95% confidence interval (CI) 81.52, 168.83) vs. 87.43 (95% CI 72.87, 104.91) for A/(H1N1)pdm, 120.45 (95% CI 82.17, 176.57) vs. 97.86 (95% CI 81.34, 117.44) for A/H3N2 and 143.32 (95% CI 103.46, 198.53) vs. 145.54 (95% CI 122.35, 174.24) for influenza B, respectively. After adjusting for confounding factors, time since transplantation was not associated with response to vaccination. No cases of rejection or severe adverse events were detected in patients vaccinated within the first 6 months after transplantation. In conclusion, influenza vaccination within the first 6 months after transplantation is as safe and immunogenic as vaccination thereafter. Thus, administration of the influenza vaccine can be recommended as soon as 1 month after transplantation.
Published: 2015

18. Tratamiento de adenocarcinoma prostático localizado en paciente con trasplante renal mediante Ultrasonido de Alta Intensidad

Author: A. Alvarado, E. Lledó García, C. Hernández Fernández, J.Mª Díez Cordero, D. Subirá Ríos, J. Jara Rascón, and F. Anaya Fernandez De Lomana
Subjects: Gynecology, medicine.medical_specialty, Cáncer de próstata, business.industry, medicine.medical_treatment, Urology, Ultrasound, Cancer, medicine.disease, High-intensity focused ultrasound, Prostate cancer, Trasplante renal, medicine.anatomical_structure, Prostate, Ultrasonido de alta intensidad, Adenocarcinoma, Medicine, Radiology, Implant, business, Kidney transplantation
Abstract: Resumen Presentamos el caso de un paciente de 62 anos portador de un trasplante renal (TR) que fue diagnosticado a los 6 anos del implante de adenocarcinoma prostatico (CP) localizado. Tras evaluar las alternativas terapeuticas se opto por el Ultrasonido de Alta Intensidad (HIFU) por via transrectal. El resultado ha sido satisfactorio, con ingreso de 24 horas, resolucion histologica y bioquimica y minima morbilidad. No hemos hallado en la literatura referencias a la utilizacion de HIFU en CP en la poblacion de trasplantados renales. Creemos que puede representar una buena alternativa terapeutica.
Published: 2005

19. Monitoring of Circulating Antibodies in a Renal Transplantation Population: Preliminary Results

Author: J. L. Vicario, David Arroyo, Antonio Balas, M.L. Rodríguez Ferrero, Nayara Panizo, and F. Anaya
Subjects: Adult, Graft Rejection, Male, Reoperation, medicine.medical_specialty, Time Factors, Basiliximab, Recombinant Fusion Proteins, Population, Renal function, Gastroenterology, Antigen, HLA Antigens, Isoantibodies, Monitoring, Immunologic, Risk Factors, Internal medicine, medicine, Humans, Prospective Studies, education, Prospective cohort study, Aged, Antilymphocyte Serum, Aged, 80 and over, Transplantation, education.field_of_study, Kidney, business.industry, Incidence, Histocompatibility Antigens Class I, Panel reactive antibody, Antibodies, Monoclonal, Middle Aged, Kidney Transplantation, Treatment Outcome, medicine.anatomical_structure, Spain, Acute Disease, Immunology, Female, Surgery, business, Biomarkers, Immunosuppressive Agents, medicine.drug
Abstract: Background The presence of circulating antibodies (CA) against human leukocyte antigen (HLA) and major-histocompatibility-complex class I–related chain A (MICA) antigens has been associated with worse renal function and reduced kidney allograft survival. We sought to describe the presence of donor-specific anti-HLA antibodies, non-donor specific antibodies, and antibodies against MICA antigens among a cohort of renal transplant recipients with respect to their evolution effects on renal function and occurrence of an acute rejection episode (AR) after transplantation. Methods This prospective study of 22 renal transplant recipients of deceased donor kidneys underwent studies of antibodies before and 3 months after grafting using Luminex technology. Results Ten patients (five men and five women) showed preexistent CA. Comparing patients with versus without preformed CA, we did not observe a significant difference in donor and recipient age or gender. Eight patients (80%) with CA had undergone induction treatment with anti-human-activated T-lymphocyte rabbit immunoglobulin and 2 (20%) with basiliximab. There were no differences between groups regarding the incidence of acute rejection episodes (ARE n = 3 each). There was one case of Banff grade IIB ARE in a patient without preexisting CA; the other episodes were low-grade cellular responses. There were no differences in other variables including cold ischemia time, HLA mismatches, panel-reactive antibody levels, number of transfusions, cytomegalovirus infection or renal function at discharge and 3 months later. Retransplantation was the only factor associated with preformed CA. Retransplantation and preformed CA were associated with CA at 3 months after transplantation. Conclusions CA monitoring is important for highly sensitized renal transplants, although our experience failed to show a difference in graft survival or renal function in the first 3 months' follow-up.
Published: 2012

20. SP065DESCRIPTIVE ANALYSIS OF AN HISTORICAL COHORT OF PATIENTS WITH THROMBOTIC MICROANGIOPATHY (TMA)

Author: María Soledad García de Vinuesa, Patrocinio Rodriguez, F. Anaya, Alba Santos, Ãšrsula Verdalles, Marian Goicoechea, Ana García-Prieto, Tania Linares Grávalos, José Luño, and Nicolás Macías
Subjects: Transplantation, medicine.medical_specialty, Thrombotic microangiopathy, Nephrology, business.industry, Internal medicine, Medicine, business, medicine.disease, Historical Cohort
Published: 2017

21. Diabetes neonatal permanente asociada a hipotiroidismo, sordera y rasgos dismórficos

Author: P. Giralt Muiña, F. Anaya Barea, A. Rosa García, G. Lledó Valera, J. Sánchez del Pozo, and M.aT. García Silva
Subjects: Hypothyroidism, Pediatrics, Perinatology and Child Health, Neonatal diabetes, Neurosensory deafness, Newborn, Malformation, Pediatrics, RJ1-570
Abstract: La diabetes mellitus neonatal se define como una hiperglucemia detectada durante el primer mes de vida, de más de 2 semanas de duración, que precisa tratamiento con insulina. Es muy rara (1/500.000 recién nacidos) y sólo el 30 % de los casos es permanente. Se han postulado variashipótesis sobre su etiología, tales como inmadurez pancreática, isodisomía del cromosoma 6 paterno o la existencia de un gen ocalizado en la región cromosómica 6q22-23 sometido a impregnación y de expresión exclusivamente paterna. Se caracterizan por ser pacie tes de difícil tratamiento, bajo peso para su edad gestacional y no se detectan anticuerpos antiinsulina ni antiislotes.Se ha estudiado un recién nacido ingresado por bajo peso para la edad gestacional con rasgos dismórficos e hiperglucemia desde el día 17 de vida. Se realiza el seguimiento clínico y analítico periódico hasta la actualidad, en el que se ha observado se trata de una diabetes neonatal permanente con anticuerpos negativos, y de difícil tratamiento a pesar de utilizar diversas pautas insulínicas desde el inicio del cuadro, hipotiroidismo, sordera neurosensorial bilateral,catarata congénita bilateral, miopía, rasgos dismórficos, estridor congénito y curva ponderostatural lenta. El estudio de biopsia muscular y metabólico fue normal. Se descartó un síndrome de Wolfram y una diabetes mitocondrial.Se trata de un caso excepcional de diabetes neonatal permanente asociado a otras malformaciones no encuadrable dentro de un patrón sindrómico conocido. : Neonatal diabetes mellitus is defined as hyperglycemiadetected in the first month of life of more than 2 weeks’ duration, requiring insulin treatment. It is extremely uncommon (1/500,000 neonates) and is permanent in only30 % of cases. Several hypotheses concerning its etiologyhave been postulated, such as pancreatic immaturity, paternal uniparental isidisomy of chromosome 6, and theexistence of a gene located in the 6q22-23 chromosome region subjected to imprinting and exclusively of paternalexpression. The management of these patients is usuallydifficult. These neonates are underweight for their gestational age, and neither anti-insulin antibodies nor anti-is-lets are detected.We studied a neonate hospitalized because of low weightfor his gestational age with dimorphic features and hyperglycemia since the 17th day of life. Clinical and anatomical follow-up has been periodically performed to the present date. The child presents permanent neonatal diabetes with negative antibodies. Although various insulinpatterns have been used since the onset of the syndrome,management remains difficult. The child presents hypothyroidism, bilateral neurosensory deafness, bilateralcongenital cataract, myopia, dimorphic features, congenital stridor and slow weight-stature curve. The results ofmuscle biopsy and metabolic studies were normal. Wolfram’s syndrome and mitochondrial diabetes were ruledout. This is an exceptional case of permanent neonatal diabetes associated with other malformations correspondingto no known syndromic patterns.
Published: 2001

22. Incidencia en menores de 16 años y prevalencia de la diabetes mellitus tipo 1A en la provincia de Ciudad Real

Author: F. Anaya Barea, D. Madrigal Barchino, A. Merlo Garrido, L. Santillana Ferrer, P. Giralt Muiña, and B. Toledo de la Torre
Subjects: Type 1A diabetes mellitus, Epidemiology, Incidence, Pediatrics, Perinatology and Child Health, Prevalence, Pediatrics, RJ1-570
Abstract: Antecedentes: Al carecer de estudios previos en nuestra provincia sobre diabetes mellitus tipo 1A se realizó el presente trabajo para conocer el estado actual en nuestro medio, y valorar en el futuro, la evolución de la enfermedad crónica más frecuente en la infancia. Objetivos: Determinar la prevalencia de la diabetes mellitus tipo 1 (DM1A) y la incidencia en menores de 16 años en la provincia de Ciudad Real. Material y métodos: Se trata de un estudio epidemiológico, observacional de tipo transversal. Se utilizó el método captura-marcaje-recaptura para el cálculo de la exhaustividad. Los pacientes se recogieron mediante encuesta en centros de salud, registros hospitalarios y asociaciones de diabéticos de la provincia. Para el cálculo de la prevalencia se incluyeron todos los diabéticos tipo 1A y para el cálculo de la incidencia se incluyen aquellos diabéticos en los que la enfermedad se inició en 1999. Resultados: La incidencia de diabetes mellitus en menores de 16 años ha sido de 26,0/100.000; se detectaron 23 niños, con una tasa de exhaustividad del 88,5%. La prevalencia de la DM1 en menores de 16 años es de 2,1/1.000 y de 0,42/1.000 habitantes de la provincia. En la población general la prevalencia es de 0,88/1.000 habitantes. Conclusiones: La incidencia de la diabetes mellitus en menores de 16 años y la prevalencia de la DM1A en la provincia de Ciudad Real es mayor de la esperada, siendo la mayor de las conocidas en España en la actualidad. Background: Because of the lack of data from our province, we performed the present study to determine the current situation and future evolution in our region of the most frequent chronic disease in childhood. Objective: To evaluate the incidence of diabetes mellitus and the prevalence of type 1A diabetes mellitus in children younger than 16 years old from the province of Ciudad Real. Material and methods: We performed an epidemiological, cross-sectional, observational study. The mark-release-recapture method was used to calculate exhaustivity. The patients were selected through surveys to primary care centers, hospital registries and diabetics associations in our province. All type 1A diabetics were included in the calculation of prevalence. Only diabetics with onset of symptoms in 1999 were included in the calculation of incidence. Results: The incidence of diabetes mellitus in children younger than 16 years old was 26 per 100,000. Twenty-three children were diagnosed with the disease, with an exhaustivity rate of 88.5%. The prevalence of type 1A diabetes mellitus in children younger than 16 years old was 2.1 per 1,000 and 0.42 per 1,000 inhabitants. The prevalence in the general population was 0.88 per 1,000 inhabitants. Conclusions: The incidence of diabetes mellitus in children younger than 16 years old and the prevalence of type 1A diabetes mellitus in the province of Ciudad Real are higher than expected and are the highest of currently known rates in Spain.
Published: 2001

23. Rituximab and Chronic Plasmapheresis Therapy of Nephrotic Syndrome in Renal Transplantation Patients With Recurrent Focal Segmental Glomerulosclerosis

Author: J. Ampuero, F. Anaya, and M. Rodríguez-Ferrero
Subjects: Adult, Male, Reoperation, medicine.medical_specialty, Nephrotic Syndrome, Biopsy, medicine.medical_treatment, Urology, urologic and male genital diseases, Antibodies, Monoclonal, Murine-Derived, Focal segmental glomerulosclerosis, Recurrence, Humans, Immunologic Factors, Medicine, Kidney transplantation, Transplantation, Proteinuria, Glomerulosclerosis, Focal Segmental, business.industry, Antibodies, Monoclonal, Plasmapheresis, medicine.disease, Combined Modality Therapy, Kidney Transplantation, Immunology, Female, Surgery, Rituximab, medicine.symptom, business, Nephrotic syndrome, Follow-Up Studies, Kidney disease, medicine.drug
Abstract: Focal segmental golmerulosclerosis (FSGS) recurs in 30% of patients with FSGS who received a first renal transplant and in more than 80% of patients receiving a second transplant after a recurrence. Plasmapheresis (PP) can reduce proteinuria and even induce complete remission of proteinuria. We studied the effects of rituximab therapy associated with chronic PP treatment of nephrotic syndrome among 3 adult renal transplant recipients with recurrent FSGS after a fourth, a second, or a third transplantation, respectively. All of these subjects had displayed recurrences in previous transplants. The 3 patients were treated with PP once a week after recurrence; the first and second patients were treated with PP before transplantation surgery seeking to prevent FSGS recurrence. The patients' follow-up times were 21, 35, and 33 months, respectively, before rituximab therapy. During that time, the patients were treated with 133, 62, and 94 PP sessions, respectively. All of the patients received rituximab (375 mg/m(2)/wk, 4 doses) and 1 PP session before each rituximab dose. We confirmed the effectiveness of rituximab therapy by demonstrating peripheral CD19 cells to be undetectable after therapy. None of the patients treated with rituximab achieved remission of proteinuria. One patient showed proteinuria reduced by 26%, the second by 44%, and the third had no change. None of the patients had infectious complications or graft loss at 1 month follow-up. Our experience with 3 adult renal transplant recipients with recurrent FSGS and chronic PP therapy showed failure of rituximab to achieve remission in nephrotic syndrome.
Published: 2009

24. Renal Function in Patients With Cadaveric Kidney Transplants Treated With Tacrolimus or Cyclosporine

Author: M. J. Cabello, F. Valdes, Javier Morales, A. Andrés, L. Capdevila, D. Del Castillo, M. Arias, Fernando Escuin, Roberto Marcén, Frederic Oppenheimer, Salvador Gil-Vernet, L. Pallardó, J. M. Campistol, Dolores Burgos, Jesus Bustamante, Ildefonso Lampreave, M. Gonzalez Molina, F. Anaya, and Daniel Serón
Subjects: Adult, Male, medicine.medical_specialty, Urology, Renal function, Kidney Function Tests, urologic and male genital diseases, Tacrolimus, chemistry.chemical_compound, Cadaver, medicine, Humans, Kidney transplantation, Aged, Retrospective Studies, Antibacterial agent, Transplantation, Creatinine, Kidney, business.industry, Middle Aged, medicine.disease, Kidney Transplantation, Tissue Donors, Surgery, surgical procedures, operative, medicine.anatomical_structure, chemistry, Cyclosporine, Female, business, Immunosuppressive Agents, Kidney disease
Abstract: Introduction. Renal function predicts graft survival in kidney transplant patients. This study compared the 2-year evolution of renal function in patients treated with cyclosporine or tacrolimus in combination with mycophenolate mofetil (MMF) and prednisone. Methods. We studied 1558 cadaveric renal transplant recipients from 14 Spanish hospitals between January 2000 and December 2002. Of these, 1168 were treated with tacrolimus and 390 with cyclosporine. The primary efficacy endpoint was long-term renal function. Renal function was measured by serum creatinine and glomerular filtration rate (GFR) by creatinine clearance calculated from the Cockcroft-Gault formula. This report summarizes the 2-year results. Results. At 24 months the tacrolimus group showed significantly better serum creatinine (1.5 ± 0.7 vs 1.8 ± 0.8 mg/dL, P
Published: 2007

25. VISCERAL LEISHMANIASIS (KALA-AZAR) IN TRANSPLANT RECIPIENTS

Author: Francisco Gómez-Campderá, Juan Berenguer, Santiago Moreno, Belén Padilla, Marisa Rodriguez-Ferrero, Fernando Valderrábano, and F. Anaya
Subjects: medicine.medical_specialty, Opportunistic infection, Antiprotozoal Agents, Leishmania donovani, Organ transplantation, Postoperative Complications, Bone Marrow, medicine, Animals, Humans, Serologic Tests, Leishmania, Transplantation, biology, business.industry, Middle Aged, medicine.disease, biology.organism_classification, Kidney Transplantation, Dermatology, Surgery, medicine.anatomical_structure, Visceral leishmaniasis, Leishmaniasis, Visceral, Pancreatitis, Female, Bone marrow, Complication, business
Abstract: Background. In endemic areas, visceral leishmaniasis has been identified as an opportunistic infection in patients with derangements in their cellular immune system. Methods. We report a renal transplant patient with visceral leishmaniasis. We also reviewed the previously published cases of 17 organ transplant recipients with this parasitic disease. Results. Visceral leishmaniasis occurred a median time of 8 months after transplantation, and the clinical picture was characterized by fever, splenomegaly, and blood cytopenias. Leishmaniae were detected in bone marrow in 16 of 18 patients and diagnostic serology results were found in 8 of 10 tested patients. Pentavalent antimonials were used to treat 16 patients, five of which developed pancreatitis. Five of 18 patients died, including two untreated patients. Relapses of visceral leishmaniasis occurred in 4 of 13 survivors. Conclusions. In endemic areas, visceral leishmaniasis may complicate the clinical course of organ transplantation and can have fatal consequences, particularly when untreated.
Published: 1998

26. Kupfer(II)-Komplexe von N-Benzoyl-O-methyl-N′-phenyl-isoharnstoffen

Author: J. Angulo Cornejo, Joachim Sieler, Lothar Beyer, F. Anaya Melendez, and Rainer Richter
Subjects: Inorganic Chemistry, chemistry.chemical_compound, Oxygen atom, chemistry, Hydrogen bond, Intramolecular force, Polymer chemistry, Molecule, chemistry.chemical_element, Methanol, Copper, Single crystal
Abstract: Durch Umsetzung von N-Benzoyl-N′-(p-nitro- bzw. p-brom-)phenyl-thioharnstoffen mit Kupfer(II)acetat-monohydrat in Methanol entstehen schwerlosliche Kupfer(I)-Niederschlage, aus deren Filtraten Bis[N-benzoyl-O-methyl-N′-(p-nitrophenyl)-isoureato]kupfer(II) 1 bzw. Bis[N-benzoyl-O-methyl-N′-(p-bromphenyl)-isoureato]kupfer(II) 2 kristallin isoliert werden. Die Molekulstruktur von 1 mit planarer trans-Koordination wurde durch Rontgenkristallstrukturanalyse bestimmt. N-Benzoyl-O-methyl-N′-(o-nitrophenyl)-isoharnstoff 3 bzw. N-Benzoyl-O-methyl-N′-(p-bromphenyl)-isoharnstoff 4 wurden aus den entsprechenden N-Benzoyl-N′-phenyl-thioharnstoffen mit Quecksilber(II)acetat in Methanol dargestellt. Die Molekulstruktur von 3 wurde durch eine Rontgenkristallstrukturanalyse bestimmt. Die NH-tautomere Form wird dabei durch eine gegabelte intramolekulare Wasserstoffbrucke zu einem Sauerstoffatom der o-Nitro-Gruppe und zum Benzoylsauerstoffatom stabilisiert. ESCA-, NMR- und massenspektrometrische Untersuchungen belegen ebenfalls die Strukturen. Copper(II) Complexes of N-Benzoyl-O-methyl-N′-phenyl-isoureas By reaction of N-benzoyl-N′-(p-nitro/p-bromphenyl)thioureas with copper(II)acetate-monohydrate in methanole insoluble copper(I)precipitates have been obtained, from which filtrates bis[N-benzoyl-O-methyl-N′-(p-nitrophenyl)-isoureato]copper(II) 1 and bis[N-benzoyl-O-methyl-(p-bromphenyl)-isoureato]copper(II) 2 were isolated. The moleculare structure of 1 with planar trans coordination has been determined by single crystal X-ray diffraction methods. The N-benzoyl-O-methyl- N′-(o-nitrophenyl)-isourea 3 and N-benzoyl-O-methyl-N′-(p-bromphenyl)-isourea 4 have been prepared by reaction of the corresponding N-benzoyl-N′-phenyl-thioureas with mercury(II)acetate in methanolic solution. The molecular structure of 3 has been determined by single crystal X-ray diffraction methods. The NH-tautomeric form is stabilized by a bifurcated intramolecular hydrogen bond to an oxygen atom of the o-nitro group and the benzoyl oxygen atom. XPS, NMR and mass-spectrometric investigations also confirm the structures.
Published: 1998

27. Posttransplant Diabetes Mellitus in Renal Allograft Recipients: A Prospective Multicenter Study at 2 Years

Author: Daniel Serón, M. Arias, D. del Castillo, Ildefonso Lampreave, L. Capdevila, A. Andrés, José M. Morales, F. Valdes, Roberto Marcén, L. Pallardó, Frederic Oppenheimer, M. Gonzalez-Molina, F. Anaya, Fernando Escuin, Jesus Bustamante, Campistol Jm, and Salvador Gil-Vernet
Subjects: Adult, Male, medicine.medical_specialty, Time Factors, medicine.medical_treatment, Urinary system, Gastroenterology, Body Mass Index, Postoperative Complications, Adrenal Cortex Hormones, Internal medicine, Diabetes mellitus, Diabetes Mellitus, medicine, Humans, Transplantation, Homologous, Cumulative incidence, Prospective Studies, Kidney transplantation, Transplantation, business.industry, Incidence, Incidence (epidemiology), Immunosuppression, Middle Aged, medicine.disease, Kidney Transplantation, Tacrolimus, Surgery, Drug Therapy, Combination, Female, business, Immunosuppressive Agents, Follow-Up Studies
Abstract: The purpose of this study was to investigate the incidence and risk factors for the development of diabetes mellitus after kidney transplantation (PTDM). A total of 1783 nondiabetic renal allograft recipients transplanted from January 2000 to December 2002 were included. Diabetes was diagnosed following American Diabetes Association criteria. While 1276 patients were treated with tacrolimus (Tac), mycophenolate mofetil (MMF), and steroids, 507 patients received cyclosporine-ME (CsA), MMF, and steroids. PTDM incidence at 6, 12, and 24 months was 14.2%, 12.8%, and 13.3%, respectively. Cumulative incidence during the follow-up was 21.6%. Only 121 of the diabetic patients (47.6%) at 6 months remained diabetic at 24 months. Furthermore, 60 patients of 116 patients on insulin at 6 months (51.7%) remained on treatment at 24 months. The cumulative incidence of PTDM was similar in the two immunosuppressive treatments (19.7% on CsA-MMF vs 22.3% on Tac-MMF; P = NS). However, at 24 months, 14 of 50 diabetic patients on CsA-MMF (28%) and 74 of 161 patients on Tac-MMF (45.9%) were on insulin treatment (P.05). By Cox regression analysis, age older than 60 years (RR 1.61; 95%CI 1.28-2.04; P.001), body mass index (BMI)30 kg/m2 at transplantation (RR 1.66; 95%CI 1.27-2.16; P.001), and immunosuppression with Tac (RR 1.30; 95%CI 1.02-1-66; P = .033) were associated with PTDM. In conclusions, the incidence of PTDM at 24 months in immunosuppressive protocols including MMF is about 22%, and it is associated with older age, increased BMI, and immnunosuppression with Tac.
Published: 2006

28. Metástasis esfenoidal de un carcinoma de células trancisionales de la vejiga

Author: J.M. Molina Ruiz del Portal, J. Segura, A. Robles, E. Solis, J.M. Castilla, and F. Anaya
Subjects: Gynecology, medicine.medical_specialty, Otorhinolaryngology, business.industry, medicine, business
Abstract: Resumen Las metastasis en los senos paranasales son extremadamente raras. En el ano 2001 apenas existian 100 casos publicados en distintas revisiones. Cuando ocurren, el tumor primario asienta con mayor frecuencia en el rinon. El seno maxilar es el mas frecuentemente afectado, el esfenoidal el mas raro. Presentamos un raro caso de metastasis en el seno esfenoidal de un carcinoma de celulas trancisionales de la vejiga.
Published: 2006

29. Contents, Vol. 72, 1996

Author: Hiroshi Toma, L. Raffaele, V. Dalmastri, Filippo Salvati, Divyesh M. Bhatt, Hiroshi Ishida, Hikaru Sugimoto, Juan M. Gonzalez, Salih Hazar, J. Guiserix, Kyoko Kurose, V. Stefanović, Majed Odeh, Hiroshi Inuma, Kamberi Perparim, Nilwarangkur S, L. Perini, F. Locatelli, Peter Nilsson-Ehle, Shigeo Takebayashi, N. Seyrek, G. Paunović, Vivette D. D'Agati, J.C. Boulanger, Mohamed A. El-Shahawy, Smaragdi Antonopoulou, M. Dapporto, Hiroshi Mabuchi, Syuko Yamamoto, Hiroshi Kitamura, Yong Goo Kim, A.G. Brox, G. Erba, R. Margreiter, Hiroshi Osawa, Hiroyoshi Matsukura, M. Vedovato, Der-Cherng Tarng, Hiromichi Suzuki, Ching-Huai Huang, Constantinos A. Demopoulos, R.F. Gagnon, Yahya Sagliker, D Di Landro, M. Oh, Shuichi Hatakeyama, Panos Ziroyiannis, A. Michault, Masateru Kawabata, P. Finielz, I. Guarnori, R. Pérez-García, Satoru Tsunoda, Shinsuke Nomura, F. Malacarne, Zensuke Ota, Byung Kee Bang, G. Ricci, Per Kjellstrand, Sompong Ong-ajyooth, Y. Sagliker, Gengo Osawa, Mark W. Majesky, Tadashi Asami, Hideaki Yamabe, L.P.W.J. van den Heuvel, Young Ok Kim, F. Fabrizi, Satsuki Yamada, H.A. Jalil, Arie Oliven, Takao Kohsaka, Hans-Georg Classen, Arturo Borsatti, B. de Cagny, R. Mallmann, M. Lago, Christos Iatrou, Yoshiharu Hiratsuka, Tanekazu Harada, Luan D. Truong, Ank Nurol, Masaki Kobayashi, Watanachai Susaengrat, Yoshiko Fujita, G.F. Romagnoli, Saime Paydas, Rainer Nobiling, D. Oefner, J.P. Mallie, George Moustakas, Syunji Ishihara, Zhi-Hong Liu, Kogo Onodera, Sumalee Nimmannit, G. Devulder, Marian Klinger, J. Radivojević, Chairat Shayakul, P. Fievet, Susumu Inaba, Masaaki Nakayama, Akira Noguchi, B. Athmani, T. Dimitrov, Emine Kocabaş, Phannee Pidetcha, P. Fardelone, Fumihiko Hinoshita, Raja I. Zabaneh, Hiroshi Nihei, M. Hattori, C. Raimondi, Naoko Yusa, Todd S. Ing, Hirofumi Makino, Manuel Martinez-Maldonado, Kouichi Hirayama, Björn Holmquist, Jesús Montoliu, P. Gilli, Hirokazu Okada, Hisashi Ozasa, Mitsuaki Kaizuka, Stefan H. Jacobson, Ichiro Koni, C. Aichberger, Augusto Antonello, David J. Leehey, R. Makdassi, A.F. van Lieburg, Masami Matsumura, Osamu Sakai, I. Pejčić, Toshio Okada, Yoshiaki Fujimiya, Miwako Arai, Hans Thysell, Seunghun Lee, Yu-Li Cho, V. Djordjević, David P. Brooks, Chul Woo Yang, Huan-Sheng Chen, Makoto Katagiri, Julio Ramos, William J. Kimberling, Kosuke Ota, Jackson Joe Yium, Paritosh Tiwari, M. Andréjak, Gary E. Striker, G. Pontoriero, P. Vaillant, Tung-Po Huang, Roberto Barrios, A. Peco-Antić, H. Sonnenberg, Osamu Hotta, Kaoru Sakai, Prida Malasit, Chie Inoue, Liliane J. Striker, Kandemir Tolga, Lorenzo A. Calò, Scott O. Trerotola, Stephen V. Foster, PeterMaria Rob, Salvatore Cantaro, Yoshihiko Kanno, V. Stojanov, Ann M. Johnson, A. Fournier, F. Zhang, Kosaku Nitta, Alex W. Yu, Richard Skroeder, P. Dennis DePalma, Keitaro Yokoyama, W. Proesmans, G. Guerra, Koji Kawamura, Merit F. Gadallah, M. Gowrishankar, I. Cheong, Eiko Suzuki, Klaus Sack, Maria Golato, Silvana Favaro, Byung Kee Kim, S. Di Filippo, J. Gondry, Necmi Aksaray, Akira Yamada, D. Marcelli, Nobuo Watanabe, Adam Bahattin, Makoto Uchiyama, Michihiro Gotoh, E. Sestigiani, Naoto Yamaguchi, Patricia A. Gabow, Stawomir C. Zmonarski, C. Campieri, Kenichi Shikata, Kennichi Shiroto, Steven Foster, I. Constant, Katsuhiko Sudo, A. Giudicissi, Ulf Nilsson, L. Neri, Kunimasa Yan, Regina R. Verani, Shuichi Tomisawa, Je Hoon Lee, M. Avramović, Akpolat Tekin, Chih-Wei Yang, Stanistaw Miękisz, Mercè Borràs, Haruki Nagahana, A. Koenigsrainer, Jerzy W. Mozrzymas, S. Stefoni, M.L. Halperin, Margret Arnadottir, Sigeko Hara, Naoyuki Tamura, Tsutomu Takahashi, Ikuo Horigome, Hidehiko Kawato, M. Ramdane, Yoshio Taguma, Yukiyoshi Nakamura, Chege J. Mukuria, F. Anaya, Satoshi Iwabuchi, Jana Pindur, L.M. Ho, M. Zompatori, Tetsuo Shibata, Ettore Tresca, V.V.A.M. Knoers, Touru Nishihara, L.A.H. Monnens, Ichiro Kajiwara, Akio Koyama, M. Crepaldi, Yoshindo Kawaguchi, Youji Ogawa, M.S. Garcia de Vinuesa, J.M. Hoarau, Shigeru Horita, Scott J. Savader, Wadi N. Suki, Bedir Abdülkerim, E. Lobjoie, Yuki Sakai, Hiroaki Muramoto, Andrzej Teisseyre, Han-Nan Liu, Tun-Jun Tsai, G. Bacchini, Hitoshi Ebata, Yung-Ming Chen, E. De Paoli Vitali, D. Toncheva, M. Kostić, Maria José Panadés, E. David, F. Valderrábano, Monica Rizzolo, Mario Liani, Yosuke Ogura, G.K. Richards, Catherine I. Lai, Angela D'Angelo, Nobuhide Mimura, Takao Saruta, Masaru Nasu, V. Bonomini, Neslihan Seyrek, Yoshio Suzuki, Somkiat Vasuvattakul, V. Parezanović, Theodore P. Labus, Masaharu Naiki, Shaul G. Massry, Yasuo Magari, S. Paydas, and Ryokichi Yasumori
Subjects: Traditional medicine, business.industry, Medicine, business
Published: 1996

30. High-sensitivity troponin T levels in kidney transplant recipients

Author: Nicolás Macías, David Arroyo, Javier Reque, Nayara Panizo, M. Rodríguez-Ferrero, Borja Quiroga, José Luño, and F. Anaya
Subjects: Adult, Male, medicine.medical_specialty, Population, Renal function, Gastroenterology, Asymptomatic, chemistry.chemical_compound, Sex Factors, Troponin T, Interquartile range, Predictive Value of Tests, Risk Factors, Internal medicine, medicine, Humans, education, Aged, Immunoassay, Transplantation, Creatinine, Univariate analysis, education.field_of_study, Chi-Square Distribution, business.industry, Age Factors, Middle Aged, medicine.disease, Kidney Transplantation, Up-Regulation, Endocrinology, Cross-Sectional Studies, Logistic Models, Treatment Outcome, chemistry, Cardiovascular Diseases, Multivariate Analysis, Surgery, Female, medicine.symptom, business, Biomarkers, Kidney disease, Glomerular Filtration Rate
Abstract: Cardiovascular disease (CVD) is still the leading cause of death among kidney transplant recipients. Validated biomarkers are important to identify patients at high risk for cardiovascular events and mortality. Cardiac troponins are one of the best available prognostic markers in this clinical situation, especially in chronic kidney disease and kidney transplant (KT) patients. The recently appeared high-sensitivity immunoassay to measure troponin T (hsTnT) has not yet been widely studied in the transplant population. We designed a cross-sectional study to evaluate hsTnT levels among 177 stable, asymptomatic patients, including 44.1% (78) males of overall mean age of 56.14 ± 14.25 years. Mean glomerular filtration rate estimated with the MDRD-4 (eGFR MDRD) formula was 48.93 ± 26.46 mL/min/1.73 m2. Median hsTnT was 11 (interquartile range = 11–26) ng/L. Patients were classified according to their hsTnT levels: normal, below 14 ng/L (57.6%, n = 102 patients), and those with basally elevated levels. Upon univariate analysis, a significant association was found between higher hsTnT levels and several variables, including clinical features, such as age, sex or prior CVD; renal function indicators: creatinine, eGFR MDRD, and proteinuria; nutritional and inflammation markers: albumin, ferritin, and C-reactive protein; and several cardiac enzymes: creatine kinase myocardial band (CKMB), B-type natriuretic peptide, and its N-terminal fragment. A logistic regression model adjusted for age, sex, and variables significantly associated with higher hsTnT levels, showed that male gender, age, CKMB, and lower glomerular filtration rate to show independent relation to basally elevated levels of hsTnT among asymptomatic kidney transplant recipients.
Published: 2012

31. Risk factors for graft loss and mortality after renal transplantation according to recipient age: a prospective multicentre study

Author: José M. Morales, Roberto Marcén, Ildefonso Lampreave, Daniel Serón, Domingo del Castillo, Federico Oppenheimer, F. J. Gainza, M. Gonzalez-Molina, F. Anaya, Mercedes Cabello, Manuel Arias, Jesus Bustamante, Fernando Escuin, Amado Andrés, Salvador Gil-Vernet, Luis M Pallardó, and Francisco Valdés
Subjects: Adult, Graft Rejection, Male, medicine.medical_specialty, Time Factors, Survival, Riñones - Trasplante, graft survival, 3205.01 Cardiología, Renal function, Riñones - Enfermedades, patient survival, Age Distribution, cardiovascular mortality, Risk Factors, medicine, Humans, Prospective Studies, Prospective cohort study, Survival rate, Kidney transplantation, Cause of death, Transplantation, Proteinuria, Supervivencia, 3205.06 Nefrología, business.industry, renal function, Original Articles, renal transplantation, Middle Aged, medicine.disease, Kidney Transplantation, Tacrolimus, Surgery, Survival Rate, surgical procedures, operative, Nephrology, Mortalidad, Female, medicine.symptom, business
Abstract: Producción Científica, Background. To describe the causes of graft loss, patient death and survival figures in kidney transplant patients in Spain based on the recipient’s age. Methods. The results at 5 years of post-transplant cardiovascular disease (CVD) patients, taken from a database on CVD, were prospectively analysed, i.e. a total of 2600 transplanted patients during 2000–2002 in 14 Spanish renal transplant units, most of them receiving their organ from cadaver donors. Patients were grouped according to the recipient’s age: Group A: 60 years. The most frequent immunosuppressive regimen included tacrolimus, mycophenolate mofetil and steroids. Results. Patients were distributed as follows: 25.85% in Group A (>40 years), 50.9% in Group B (40–60 years) and 23.19% in Group C (>60). The 5-year survival for the different age groups was 97.4, 90.8 and 77.7%, respectively. Death-censored graft survival was 88, 84.2 and 79.1%, respectively, and non death-censored graft survival was 82.1, 80.3 and 64.7%, respectively. Across all age groups, CVD and infections were the most frequent cause of death. The main causes of graft loss were chronic allograft dysfunction in patients 1 g at 6 months post-transplantation were statistically significant in the three age groups. The patient survival multivariate analysis did not achieve a statistically significant common factor in the three age groups. Conclusions. Five-year results show an excellent recipient survival and graft survival, especially in the youngest age group. Death with functioning graft is the leading cause of graft loss in patients >40 years. Early improvement of renal function and proteinuria together with strict control of cardiovascular risk factors are mandatory.
Published: 2012

32. Fourth meeting of the European Neurological Society 25–29 June 1994 Barcelona, Spain

Author: H. Hattig, C. Delli Pizzi, M. C. Addonizio, Michelle Davis, A. R. Giovagnoli, L. Florensa, M. Roth, J. de Kruijk, Francisco Lacruz, Ph. Dewailly, A. Toygar, C. Avendano, P.P. De Deyn, J. F. Hurtevent, F. Lomeila, T. W. Wong, Gordon T. Plant, M. Bud, H. J. Willison, DH Miller, D. W. Langdon, R. Cioni, J. Servan, A. Kaygisiz, E. Racadot, D. B. Schens, E. Picciola, L. Falip, C. Bouchard, J. Jotova, A. Jorge-Santamaria, P. Misra, A. Dufour, C. P. Panagopoulos, A. Venneri, B. Sredni, B. Angelard, M. Janelidze, M. Carreno, J. Obenberger, J. Pouget, H. W. Moser, R. Kaufmann, J. A. Molina, D. Linden, A. Martin Urda, E. Uvestad, A. Krone, J. P. Cochin, J. Mallecourt, A. Cambon-Thomsen, K. Violleau, P. Osschmann, A. M. Durocher, E. Bussaglia, D. M. Danielle, H. Efendi, C. Van Broeckhoven, K. G. Jordan, W. Rautenberg, C. Iniguez, J. M. Delgado, Graham Watson, M. Lawden, Gareth J. Barker, K. Stiasny, James T. Becker, G. Campanella, E. Peghi, A. Poli, A. Haddad, T. Yamawaki, Giacomo P. Comi, S. Sotgiu, B. Ersmark, A. Pomes, M. Ziegler, P. Ferrante, P. Ruppi, H. KuÇukoglu, R. Bouton, U. K. Rinne, P. Vieregge, M. Dary, P. Giunti, Peter J. Goadsby, S. Jung, E. Secor, A. Steinberg, N. Vila, M. A. Hernandez, M. Cursi, A. Enqelhardt, A. Engelhardt, J. Veitch, F. Di Silverio, F. Arnaud, B. Neundörfer, R. Brucher, Dominique Caparros-Lefebvre, B. Meyer, Marianne Dieterich, M. H. Snidaro, R. Gomez, R. Cerbo, M. Ragno, J. M. Vance, S. Nemni, A. Caliskan, F. Barros, I. Velcheva, D. Ceballos-Baumann, V. Barak, A. Avila, N. Antonova, F. Resche, S. Pappata, L. Varela, S. R. Silveira Santos, A. Cammarota, L. Naccache, Y. Nara, E. Tournier-Lasserves, R. Mobner, T. Chase, A. Ensenyat, J. Ulrich, G. Giegerich, M. Rother, M. Revilla, N. Nitschke, K. Honczarenko, E. Basart Tarrats, J. Blin, B. Jacob, J. Santamaria, S. Knezevic, J. L. Castillo, M. Antem, J. Colomer, O. Busse, Didier Hannequin, S. Carrier, J. B. Ruidavets, C. Rozman, J. Bogoussslavsky, J. Pascual Calvet, E. Monros, J. M. Polo, M. Zucconl, Javier Muruzabal, R. R. Allen, R. Rivolta, K. Haugaard, A. Nespolo, K. Hoang-Xuang, G. Bussone, T. Avramidis, E. Corsini, Christiana Franke, T. Vinogradova, H. Boot, K. Vestergaard, G. H. Jansen, N. Argentino, M. Raltzig, W. Linssen, Mark B. Pepys, P. Roblot, L. Lauritzen, E. Fainardi, D. Morin, T. X. Arbizu Urdiain, J. Wollenhaupt, S. Bostantjopoulou, G. Pavesi, A. D. Forman, Giovanni Fabbrini, D. Jean, J. J. Archelos, M. I. Blanchs, M. Del Gobbo, Anna Carla Turconi, Ch. Derouesné, Elio Scarpini, A. Visbeck, P. Castejon, J. P. Renou, F. Mounier-Vehier, G. Potagas, Ch. Duyckaerts, A. Filla, R. Schneider, G. Ronen, K. Nagata, J. P. Vedel, A. Henneberg, G. van Melle, C. Baratti, H. Knott, M. C. Prevett, A. Bes, B. Metin, Jos V. Reempts, L. Martorell, Mefkure Eraksoy, H. O. Handwerker, D. S. Younger, O. Oktem, D. Frongillo, C. Soriano-Soriano, L. Niehaus, F. Zipp, A. Tartaro, S Newman, R. H. Browne, P. Davous, R. Sanchez, M. Muros, M. E. Kornhuber, A. Lavarone, M. Mohr, M. R. Garcia, S. Russell, H. Kellar-Wood, M. R. Tola, B. Ostermeyer, Ch. Tzekov, K. Sartor, E. B. Ringelstein, P. P. Gazzaniga, Paul Krack, H. Fidaner, H. Rico, T. Dbaiss, F. Alameda, E. Torchiana, L. Rumbach, I. Charques, J. M. Bogaard, C. D. Frith, L. J. Rappelle, R. Brenner, A. Joutel, K. Fuxe, G. HÄcker, M. J. Blaser, J. Valls-SolÇ, G. Ulm, M. Alberdi, A. Bock, F. W. Bertelsmann, U. Wieshmann, J. Visa, J. R. Lupski, D. D'Amico, L. M. P. Ramos, A. A. Vanderbark, R. Horn, M. Warmuth, Dietmar Kühne, Mark S. Palmer, C. Ehrenheim, E. Canga, S. Viola, O. Scarpino, P. Naldi, R. Almeida, A. A. Raymond, J. Gamez, Stephan Arnold, A. DiGiovanni, J. Dalmau, C. C. Chari, H. F. Beer, J. C. Koetsier, J. Iriarte, E. Yunis, J. Casadevall, E. Le Guern, E. Stenager, S. R. Benbadis, J. M. Warter, F. Burklin, I. Theodorou, L. Johannesen, G. A. Graveland, X. Leclerc, I. Vecchio, L. Ozelius, G. Nicoletti, R. K. Gherardi, E. Esperet, M. L. Delodovici, F. Cattin, F. Paiau, Giorgio Sacilotto, C. A. J. Broere, D. Chavdarov, J. P. Willmer, C. H. Hawkes, Th. Naegele, E. Ellie, E. Dartigues, M. J. Guardiola, S. Hesse, Z. Levic, Marco Rovaris, P. Saugeir-Veber, B. A. Yaqub, H. F. Durwen, R. Larumbe, J. Ballabrina, M. Sendtner, J. Röther, M. Horstink, C. Kluglein, M.P. Montesi, H. Apaydin, J. Montoya, E. Waubant, Ch. Verellen-Dunoulin, A. Nicolai, J. Lopez-Delval, R. Lemon, G. Cantinho, E. Granieri, A. Zeviani, Wolfgang H. Oertel, U. Ficola, V. Di Piero, V. Fragola, K. Sabev, M. V. Guitera, I. Turki, F. Bolgert, P. Ingrand, J. M. Gobernado, L. M. E. Grimaldi, S. Baybas, B. Eymard, Y. Rolland, Y. Robitaille, Ta. Pampols, P. J. Koehler, A. Carroacedo, J. Vilchez, S. Di Vittorio, I. R. Rise, T. Nagy, M. Kuffner, E. Palazzini, A. Ott, J. Pruim, T. X. Arbizu, E. Manetti, C. Cervera, S. Felber, G. Gursoy, J. Scholz, G. A. Buscaino, M. S. Chen, A. Pascual, J. Hazan, J. U. Gajda, J. G. Cea, G. Bottini, G. Damalik, F. Le Doze, G. Bonaldi, J. M. Hew, C. Messina, A. M. Kennedy, J. M. Carney, N. M. F. Murray, M. Parent, M. Koepp, V. Dimova, D. De Leo, K. Jellinger, G. Salemi, S. Mientus, M. L. Hansen, F. Mazzucchelli, J. Vieth, M. Mauri, E. Bartels, L. Johannsen, C. Humphreys, J. Emile, D. N. Landon, E. Kansu, R. Sanchez-Pernaute, Rsj Frackowiak, M. Gonzalez Torres, L. Oller, C. Machedo, J. Kother, M. Billiard, H. Durak, T. Schindler, A. Frank, A. Uncini, A. Sbriccoli, C. Farinas, D. W. Paty, N. Fast, A. T. Zangaladze, A. Kerkhofs, J. M. Pino Garcia, I. De la Fuente, B. Marini, L. Gomez, I. Rubio, Alessandra Bardoni, C. Brodie, P. Acin, U. Sliwka, S. A. Hawkins, S. Tardieu, F. Vitullo, J. M. Pereira Monteino, R. Gagliardi, T. Jezewski, A. Cano, T. Lempert, F. Abad Alegria, G. Rotondo, D. Ince, C. Martinez Parra, Y. Huang, H. Luders, Y. Steinvil, F. G. A. Van Der Meche, R. Bianchi, A. Sanchez, T. Sevilla, J. M. Ketelslegers, A. Domzal-Stryga, M. Pandolfo, M. O. Josse, K. W. Neff, I. Blanco, G. W. Bruyn, O. W. Witte, J. L. Thibault, G. Andersen, J. Pariset, A. Marcone, R. J. M. Lane, A. Hofman, M. Verin, T. Matilla, P. Bedoucha, J. Roche, M. Lai, M. Collard, A. Ugarte, F. Gallecho, D. Silbersweig, C. Kennard, J. P. Azulay, T. W. Ho, P. L. I. Dellemijn, R. Girardello, F. Baas, B. Voss, F. Rozenberg, E. M. Brocker, V. Stanev, A. A. J. Soeterboek, A. Marra, A. Rey, E. Ertem, M. Sawradewicz-Rybak, J. De Keyser, P. Cavallari, F. Proust, Y. Chevalier, H. C. Hansen, D. Leys, C. A. Davie, K. Hoang-Xuan, C. Bairati, H. van Crevel, Thomas T. Warner, B. Bompais, A. Dobbeleir, T Campbell, C. Macko, C. J. M. Klijn, M. Dussallant, T. P. Berlit, W. Rozenbaum, M. J. van den Bent, W. A. Rocca, M. Muller, H. Hundemer, U. Zifko, M. Campera, F. Drislane, D. Ranoux, T. M. Kloss, Anil Kumar, I. Ruolt, C. Bargnani, B. Marescau, N. A. Losseff, S. Notermans, B. Kint, E. T. Burke, C. Aykut, J. Matias Guiu, P. Maquet, T. Drogendijk, M. Leone, K. von Ammon, M. Pepeliarska, C. Prados, L. DiGiamberardino, T. Logtenberg, G. Lenoir, I. Castaldo, Damhaut, M. Radionova, G. Sirabian, R. Navon, Giovanni Antonini, K. Al Moutaery, E. Chamas, R. Schönhuber, M. Giannini, B. Debilly, I. Labatut, H. Henon, J. A. Egido, M. Baudrimont, J. N. Lorenzo, J. E. C. Bromberg, R. Antonacci, J. J. Vilchez, T. Moulin, B. Rautenstrauss, Giovanni Meola, J. Noth, S Mammi, P. Laforet, F. Lopez, C. Gehring, S. Bort, G. Rancurel, D. Decamps, S. Kostadinova, Y. Shapira, B. Neundoerfer, D. Chavrot, M. Solimena, J. P. Salier, W. Deberdt, R. Hoff-Jörgensen, A. Messina, S. Meairs, G. Rosoklija, E. Nelis, I. Bertran, C. Ertekin, J. Lohmeyer, Mitermayer Galvao dos Reis, L. Calo, E. Maccagnano, A. P. Hays, J. Verlooy, M. G. Forno, T. Blanco, L. Bail, Gabriella Silvestri, J. Montero, F. Bertrand, R. T. Ghnassia, C. Besses, T. Sereghy, F. Shalit, G. Bogliun, S. Braghi, St. Baykouchev, C. Franke, A. Lasa, L. C. Archard, J. Kriebel, S. Shaunak, M. Nocito, Alexander Tsiskaridze, E. Manfredini, T. Seigal, David G. Gadian, M. Barlas, J. D. Degos, C. Seeber, J. Caemert, J. L. Mas, R. B. Pepinsky, M. G. D'Angelo, N. Baumann, S. Yorifuji, H. P. Endtz, M. A. Cassatella, R. A. C. Hughes, V. Golzi, A. Bittencourt, A. Ferreira, M. Sanson, C. Alper, M. Vermeulen, M. A. A. van Walderveen, E. Alexiou, C. H. Lucas, M. Fiorelli, Y. N. Debbink, R. Gil, S. Congia, T. Banerjee, J. M. Bouchard, A. N. Pinto, A. Ceballos-Baumann, G. Grollier, P. I. M. Schmitz, M. D. Catata, N. Lahat, N. S. Rao, P. Papathanasopoulos, J. Valls-Solé, D. Claus, G. Schroter, A. Castro, C. Videbaek, R. Martinez Dreke, A. D. Platts, M. Hermesl, A. C. PeÇanha-Martins, M. Cardoso Silva, P. Masnou, M. J. A. Tanner, Ch. Confavreux, B. Mishu, H. Rasmussen, L. Valenciano, Carlo Pozzilli, S. W. Li, V. Salzman, Y. Vashtang, Massimo Franceschi, M. Severo, G. Deuschl, S. Setien, G. Mariani, A. Protti, J. Castillo, M. J. B. Taphoorn, M. Frontali, I. Milonas, D. Decoq, J. A. Navarro, S. Castellvi-Pel, C. Ertikin, M. Urtasun, Y. Lajat, B. E. Kendall, E. Verdu, B. Gueguen, E. Boisen, R. Couderc, A Danek, JM Stevens, F. Nicoli, L. Feltri, M. L. Vazquez-Andre, J. A. Morgan-Hughes, L. D'Angelo, F. Y. Liew, L. F. Pascual, J. Patrignani Ochoa, Vittorio Martinelli, J. Cophignon, L. Zhang, S. Martin, J. F. Meder, H. C. Buschmann, L. Bertin, J. van Gijn, A. Barreiro, A. Cools, C. Leon, A. Berod, E. A. Anllo, E. Zanette, L. Petrov, R. Barona, B. Gallicchio, P. J. Cozzone, N. Diederich, G. Cancel, L. Schelosky, P. Orizaola, K. Yulug, S. Ozer, Valeria A. Sansone, B. Guiraud-Chaumeil, K. Voigt, P. Labauge, M. Eoli, J. Zhu, J. Aguirre, M. Ferrarini, B. Zyluk, E. Planas, A. Cadilha, C. Tortorella, H. Bismuth, C. E. Counsell, A. Laun, A. Ferlini, Rio J. Montalban, N. Biary, L. Becker, M. Fardeau, M. Poloni, V. M. S. de Bruin, C. Fornada, J. Barros, E. Ganzmann, E. Touze, D. Wallach, J. Peila, H. Fujimura, M. T. Iba-Zizen, G. Macchi, C. Villoslada, R. Gouider, Ph. Rondepierre, P. Grummich, P. Chiodi, C. Conte, M. Michels, P. Annunziata, G. Semana, C. Sommer, J. Vajsar, D. Zekin, J. Kulisevsky, David G. Munoz, B. Jacotot, M. Magoni, A. Luxen, T. Garcia-Silva, S. Di Cesare, Christophe Tzourio, M. Gomori, I. Picomell, L. Santoro, F. Villa, Giovanni Pennisi, T. Ribalta, J. M. Molto, L. Marzorati, P. Loiseau, F. Gemignani, A. Gironell, J. Wissel, A. Prusinski, F. Cailloux, P. Villanueva-Hemandez, P. Cozzone, T. Del Ser, J. Sans-Sabrafen, M. Zappia, P. W. A. Willems, G. Tchernia, D. Gardeur, R. Bauer, F. Palomo, H. Metz, S. Lamoureux, C. Chastang, I. Reinhard, A. Goldfarb, S. Harder, Jordi Río, C. Ozkara, E. Tekinsoy, P. Vontobell, J. De Recondo, M. Rabasa, L. Lacomblez, F. Boon, Dgt Thomas, V. Palma, Renato Mantegazza, A. Dervis, M. Nueckel, B. YalÇinerner, I. Duran, G. Dalla Volta, A. Zubimendi, J. Pinheiro, A. Marbini, Xavier Montalban, H. Wekerle, X. Pereira Monteino, F. Crespo, F. Koskas, N. Battistini, C. Ruiz, H. Offner, J. de Pommery, P. Kanovsky, J. Y. Barnett, J. Pardo, G. Tomei, R. Rene, H. M. Lokhorst, P. Thajeb, H. Bilgin, D. McGehee, R. Fahsold, L. Morgante, Katie Sidle, C. Delwaide, M. N. Diaye, P. H. Rice, A. Creange, C. Sabev, K. Stephan, K. WeilBenborn, G. Magnani, L. Grymonprez, F. Cardellach, M. Kaps, N. G. Meco, F. Vega, V. Bonifati, A. Desomer, M. Baldy-Moulinier, G. Kvale, F. J. Authier, B. Yegen, T. Ho, J. M. Rozet, E. A. Cabanis, L. Bruce, L. Ambrosoli, M. A. Petrella, M. Hernandez, P. Timmings, H. B. van der Worp, F. Mahieux, A. Urbano-Marquez, D. A. Krendel, A. A. Garcia, R. Divari, R. Michalowicz, M. R. Piedmonte, M. Bondavalli, M. Zanca, P. F. Ippel, Onofre Combarros, B. Tavitian, E. Hirsch, I. Anastasopoulos, A. Roses, A. Köhler, P. Vienna, V. Timmerman, P. Sergi, F. Cornelio, A. Di Pasquale, R. Verleger, S. Castellvirel, J. Proano, B. van Moll, F. Rubio, W. Hacke, I. Lavenu, L. Zetta, M. W. Tas, N. Bittmann, M. Bonamini, O. R. Hommes, V. Dousset, N. Afsar, S. Belal, R. R. Myers, J. Goes, Giuseppe Vita, E. Clementi, V. G. Karepov, M. Jueptner, A Vincent, P. Emmrich, Th. Heb, A. Caballo, J. Gallego, T. Mokrusch, C. Perla, L. Gebuhrer, O. Titlbach, Alessandro Prelle, A. Czlonkowska, M. Russo, D. Hadjiev, T. S. Chkhikvishvili, M. Oehlschlager, G. Becker, I. Günther, E. N. Stenager, J. Garcia Agundez, J. Casademont, J. Batlle, S. Podobnik-Sarkanji, C. Alonso-Villaverde, B. Delaguillaume, B. Genc, B. Mazoyer, A. Rodriguez-Al-barino, Ch. Hilger, B. Ferrero, R. Price, W. Grisold, L. Fuhry, D. Oulbani, D. Ewing, A. Petkov, W. Walther, A. Gokyigit, John Newsom-Davis, J. Tayot, D. Seliak, G. Pelliccioni, D. Campagne, K. Kessler, F. Boureau, D. Perani, J. P. N'Guyen, N. Tchalucova, B. A. Antin-Ozerkis, C. Lacroix, B. D. Aronovich, I. H. Jenkins, E. A. dos Reis, M. Hortells, H. M. Meinck, H. Ch. Buschmann, S. C. J. M. Jacobs, T. Wetter, P. Creissard, N. Martinez, J. Weidenfeldl, H. J. Sturenburg, G. Damlacik, V. Gracia, J. C. Turpin, A. Pou-Serradell, J. P. Vincent, T. Gagoshidze, U. Ozkutlu, M. McLeod, K. Siegfried, I. Tchaoussoglou, J. Hildebrand, S. Kowalska, M. C. Picot, G. Galardin, L. Crevits, F. Andreetta, S. Larumbe-Lobalde, G. de la Sierra, J. C. Alvarez-Cermeno, R. J. Seitz, P. L. Oey, L. Ptacek, A. M. J. Paans, A. Wirrwar, A. Schmied, J. Uilchez, H. Tounsi, D. Hipola, V. Avoledo, Y. Hirata, P. Vermersch, T. M. Aisonobe, J. Valls-SoIè, H. Staunton, J. Dichgans, R. Karabudak, I. Dones, G. Porta, E. Janssens, Maria Martinez, J. M. Fernandez-Real, R. Villagra, Y. Yoshino, C. Kabus, K. Schimrigk, I. Girard-Buttaz, F. Piccoli, F. Aichner, P. Zuchegna, S. M. Al Deeb, F. Bono, N. Busquets, A. Jobert, Patrizia Ciscato, M. Martin, L. Polman, S. Darbra, V. Le Cam-Duchez, F. Baldissera, B. Baykan-Kurt, D. Guez, M. Bratoeva, H. Matsui, M. Mila, H. Perron, L. Bjorge, G. Husby, Steven T. DeKosky, D. R. Cornblath, J. M. Gabriel, J. J. Poza, Y. Wu, A. Toscano, R. P. Kleyweg, J. Kuhnen, S. O. Confort-Gouny, A. Barcelo, A. M. Conti, C. Fiol, C. Steichen-Wiehn, J. Rodes, M. Cavenaile, C. Vedeler, M. Drlicek, C. Argentino, M. L. Peris, A. Cervello, A. Z. GinaÏ, S. Yancheva, D. Passingham, S. Aoba, D. L. Lopez, T. Rechlin, K. Sonka, L. Grazzi, V. Folnegovic-Smalc, Maurizio Moggio, S. Rivaud, F. G. I. Jennekens, C. H. Hartard, H. Meierkord, G. Stocklin, M. D. Catala, W. C. McKay, E. Salmon, C. Navarro, I. Pastor, L. Canafoglia, M. De Braekeleer, P. K. Thomas, C. Mocellini, C. Pierre-Jerome, M. C. Dalakas, P. Pollak, M. Levivier, Niall Quinn, G. E. Rivolta, Z. Tunca, H. Zeumer, J. Garcia Tena, St. Guily, P. Gaudray, Johannes Kornhuber, V. Petrunjashev, R. Montesanti, R. J. Abbott, H. Petit, G. Kiteva-Trencevska, F. Carletto, C. Ramo, I. M. Pino, P. Beau, G. F. Mennuni, F. Moschian, F. Meneghini, B. Zdziarska, B. Fontaine, C. Stephens, G. Meco, K. Reiners, G. Badlan, M. Sessa, I. Degaey, S. M. Hassan, C. Albani, F. Caroeller, M. Schroeder, G. Savettieri, A. Novelletto, R. Kurita, P. Oschmann, I. Plaza, M. Oliveres, Simone Spuler, A. Molins, M. Schwab, J. R. Kalden, C. P. Gennaula, Y. Baklan, O. Picard, J. M. Léger, B. Mokri, E. Ghidoni, M. Jacob, D. Deplanque, W. JÄnisch, C. De Andres, P. De Deyn, G. Guomundsson, B. Herron, J. Barado, J. L. Gastaut, Guglielmo Scarlato, F. Poron, Nicola Jones, H. Teisserenc, C. P. Hawkins, A. J. Steck, H. C. Chandler, S. Blanc, J. H. Faiss, Jm. Soler Insa, I. Sarova-Ponchas, M. Malberin, A. Sackmann, G. De Vuono, K. Kaiser-Rub, K. Badhia, E. Szwabowska-Orzeszko, S. Ramm, C. Jodice, G. Franck, J. Marta-Moreno, R. Sciolla, C. Fritz, A. Attaccalite, F. Weber, E. Neuman, M. Cannata, A. Rodriguez, I. Nachainkin, R. Raffaele, T. S. Yu, N. Losseff, E. Fabrizio, C. Khati, M. Keipes, M. P. Ortega, M. Ramos-Alvarez, E. Brambilla, A. Tarasov, K. H. Wollinsky, O. B. Paulson, F. Boller, G. Bozzato, H. Wagnur, R. Canton, D. Testa, E. Kutluaye, M. Calopa, D. Smadja, G. Malatesta, F. Baggi, A. Stracciari, G. Daral, G. Avanzini, J. Perret, J. Arenas, P. Boon, I. Gomes, A. Vortmeyer, P. Cesaro, S. Venz, E. Bernd Ringelstein, N. Milani, D. Laplane, P. Seibel, E. Tournier-Lasserve, Alexis Brice, L. Motti, E. Wascher, R. J. Abbot, F. Miralles, A. Turon, P. De Camilli, G. Luz, G. C. Guazzi, S. Tekin, F. Lesoin, T. Kryst, N. Lannoy, F. Gerstenbrand, S. Ballivet, H. A. M. van Diemen, J. Lopez-ArLandis, P. Bell, A. Silvani, M. A. Garcia, S. Vorstrup, D. Langdon, S. Ueno, B. Sander, V. Ozurk, C. Gurses, P. Berlit, J. M. Martinez-Lage, M. Treacy, S. O. Rodiek, S. Cherninkova, J. Grimaud, P. Marozzi, K. Hasert, S. Goldman, S. H. Ingwersen, A. Taghavy, T. Roig, R. Harper, I. Sarova-Pinchas, Anthony H.V. Schapira, R. Lebtahi, A. Vidaller, B. Stankov, D. Link, J. p. Malin, V. Petrova, Ludwig Kappos, J. L. Ochoa, T. Torbergsen, M. Carpo, M. Donato, Simon Shorvon, J. Mieszkowski, J. Perez-Serra, Raymond Voltz, G. Comi, S. Rafique, A. Perez-Sempere, N. Khalfallah, S. Bailleul, M. Borgers, S. Banfi, S. Mossman, A. Laihinen, G. Filippini, R. A. Grunewald, E. Stern, H. D. Herrmann, A. G. Droogan, P. Xue, A. Grilo, L. La Mantia, J. H. J. Wokke, S. Pizzul, Kie Kian Ang, S. Rapaport, W. Szaplyko, B. Romero, P. Brunet, A. Albanese, C. Davie, V. Crespi, F. Birklein, H. Sharif, L. Jose, D. Auer, N. Heye, Martin N. Rossor, C. E. Henderson, M. J. Koepp, J. Rubio, P. L. Baron, S. Mahal, Juha O. Rinne, J. I. Emparanza, S. E. C. Davies, Frederik Barkhof, M. Riva, R. E. Brenner, B. A. Pope, Lemaire, E. Dupont, D. Ulbricht, G. C. Pastorino, R. Retska, E. Chroni, A. Danielli, V. Malashkhia, T. Canet, J. C. Garcia-Valdecasas, J. Serena, R. A. Pfeiffer, B. Wirk, B. Muzzetto, V. Caruso, M. L. Giros, A. Ming Wang, E. L. E. Guern, F. Bille-Turg, Y. Satoh, C. H. Franke, M. Ait-Kaci-Ahmed, D. Genis, T. Pasierski, D. Riva, M. Panisset, A. Chamorro, P.A. van Doorn, S. Schellong, H. Hamer, F. Durif, P. Krauseneck, Y. Bahou, B. A. Pickut, M. Rijnites, H. Nyland, G. Jager, L. L. Serra, A. Rohl, X. P. Li, O. Arena, Hubert Kwieciński, N. Milpied, M. C. Bourdel, S. Assami, L. Law, J. Moszkowski, J. W. Thorpe, M. Aguennouz, R. Martin, D. Hoffmann, P. Morris, A. Destée, D. J. Charron, U. Senin, A. P. SempereE, M. Dreyfus, A. L. Benabid, M. Gomez, S. Heindle, M. C. Morel-Kopp, M. Hennerici, A. I. Santos, M. Djannelidze, N. Artemis, John Collinge, T. Rundek, M. Y. Voloshin, P. de Castro, Th. Wiethege, D. A. S. Compston, D. Schiffer, A. J. Hughes, D. Jimenez, V. Parlato, A. Papadimitriou, J. M. Gergaud, R. Sterzi, J. Arpa, G. de Pinieux, F. Buggle, P. Gimbergues, H. Ruottinen, R. Marzella, W. Koehler, Y. Yurekli, A. Haase, Z. Privorkin, G. K. Harvey, B. Chave, A. J. Grau, E. M. Stadlan, J. List, C. Zorzi, B.W. van Oosten, P. Derkinderen, B. Casati, J. M. Maloteaux, K. Vahedi, W. L. J. van Putten, J. C. Sabourin, D. Lorenzetti, Plenevaux, J. W. B. Moll, A. Morento Fernandez, M. Lema, M. A. Horsfleld, P. De Jongh, S. Gikova, K. Kutluk, Monique M.B. Breteler, P. Saddier, A. Berbinschi, R. E. Cull, P. Echaniz, H. Kober, C. Minault, V. Kramer, A. L. Edal, S. Passero, T. Eckardt, K. E. Davies, A. Salmaggi, R. Kaiser, A. A. Grasso, Claudio Mariani, G. Egersbach, Hakan Gurvit, O. Dereeper, C. Vital, L. Wrabetz, A. Vecino, M. Aguilar, G. Bielicki, H. Becher, J. Castro, S. Iotti, M. G. Natali-Sora, E. Berta, S. Carlomagno, L. Ayuso-Peralta, P. H. Rondepierre, I. Bonaventura, B. V. Deuren, N. Van Blercom, M. Sciaky, J. Faber, M. Alberoni, M. Nieto, F. Sellal, C. Stelmasiak, M. Takao, J. Bradley, D. Zegers de Beyl, H. Porsche, G. Goi, H. Pongratz, F. Chapon, S. Happe, Robin S. Howard, B. Weder, S. Vlaski-Jekic, J. M. Ferro, R. Nemni, A. Daif, Herbert Budka, W. Van Paesschen, B. Waldecker, F. Carceller, J. Lacau, F. Soga, J. Peres Serra, E. Timmerman, A. M. vd Vliet, J. L. Emparanza, N. Vanacore, A. Pizzuti, N. Marti, A. Davalos, N. Ayraud, U. Zettl, J. Vivancos, Z. Katsarou, H. M. Mehdorn, G. Geraud, M. Merlini, M. Schröter, A. Ebner, M. Lanteri-Minet, R. Soler, G. P. Anzola, S. L. Hauser, L. Cahalon, S. DiDonato, R. Cantello, M. Marchau, J. Gioanni, F. Heidenreich, J. Manuel Martinez Lage, P. Descoins, F. Woimant, J. F. Campo, M. H. Verdier-taillefer, M. S. F. Barkhof, G. J. Kemp, A. O. Ceballos-Baumann, J. Berciano, M. Guidi, Tarek A. Yousry, B. Chandra, A. Rapoport, P. Canhao, A. Spitzer, T. Maeda, J. M. Pereira Monteiro, V. Paquis, Th. Mokrusch, F. J. Arrieta, I. Sangla, F. Canizares-Liebana, Lang Chr, André Delacourte, V. Fetoni, P. Kovachev, D. Kidd, L. Ferini-Strambi, E. Donati, E. Idman, A. Chio, C. Queiros, D. Michaelis, S. Boyacigil, A. Rodrigo, S. M. Yelamos, B. Chassande, P. Louwen, C. Tranchant, E. Ciafalon, A. Lombardo, A. Twijnstra, A. L. Fernandez, H. Kott, A. Cannas, N. Zsurger, T. Zileli, E. Metin, P. C. Bain, G. Fromont, B. Tedesi, A. Liberani, X. Navarro, M. C. Rowbotham, V. Hachinski, F. Cavalcanti, W. Rostene, R. M. Gardiner, F. Gonzalez, B. Köster, E. A. van der Veen, J. P. Lefaucheur, C. Marescaux, D. Boucquey, E. Parati, S. Yamaguchi, A. S. Orb, R. Grant, G. D. P. Smith, P. Goethals, M. Haguenau, G. Georgiev, I. N. van Schaik, Guy A. Rouleau, E. Iceman, G. Fayet, M. G. Kaplitt, C. Baracchini, H. Magnusson, G. Meneghetti, N. Malichard, M. L. Subira, D. Mancia, A. Berenguer, D. Navarrete Palau, H. Franssen, G. Kiziltan, M. P. Lopez, J. Montalt, S. Norby, R. Piedra Crespo, T. L. Rothstein, R. Falip, B. YalÇiner, F. Chedru, I. W. Thorpe, F. W. Heatley, D. S. C. Ochoa, C. Labaune, M. Devoti, O. Lider, Jakob Korf, N. Suzuki, E. A. Maguire, A. Moulignier, J. C. van Swieten, F. Monaco, J. Cartron, A. Steck, B. Uludag, M. Alexandra, H. Reichmann, T. Rossi, L. E. Claveria, A. M. Crouzel, M. A. Mena, J. Gasnault, J. W. Kowalski, S. I. Mellgren, V. Feigin, L. Demisch, J. Montalban, J. Renato, J. Mathieu, N. Goebels, L. Bava, K. Kunre, M. Pulik, S. Di Donato, C. Tzekov, H. Veldman, S. Giménez-Roldan, B. Lechevalier, L. Redondo, B. Pillon, M. Gugenheim, E. Roullet, J. M. Valdueza, C. Gori, H. J. Friedrich, L. de Saint Martin, F. Block, E. Basart, M. Heilmann, B. Becq Giraudon, C. Rodolico, G. Stevanin, Elizabeth K. Warrington, A. T. M. Willemsen, K. Kunze, C. Ben Hamida, M. Alam, J. R. ùther, A. Battistel, G. Della Marca, Richard S. J. Frackowiak, F. Palau, T. Brandt, Chicoutimi, L. Bove, L. Callea, A. Jaspert, T. Klopstock, K. Fassbender, Alan J. Thomas, A. Ferbert, V. Nunes, Douglas Russell, P. Garancini, C. Sanz-Sebastian, O. Santiag, G. Dhaenens, G. Seidel, I. Savic, A. Florea-Strat, M. Rousseaux, N. Catala, E. O'Sullivan, M. J. Manifacier, H. Kurtel, T. Mendel, P. Chariot, M. Salas, D. Brenton, R. Lopez, J. Thorpe, Jimmy D. Bell, E. Hofmann, E. Botia, J. Pacquereau, A. Struppler, C. d'Aniello, D. Conway, A. Garcia-Merino, K. Toyooka, S. Hodgkinson, E. Ciusani, Stefano Bastianello, A. Andrade Filho, M. Zaffaroni, G. Pleiffer, F. Coria, A. Schwartz, D. Baltadjiev, I. Rother, K. Joussen, J. Touchon, K. Kutlul, P. Praamstra, H. Sirin, S. Richard, C. Mariottu, L. Frattola, S. T. Dekesky, G. Wieneke, M. Chatel, O. Godefroy, C. Desnuelle, S. OzckmekÇi, C. H. Zielinski, P. van Deventer, S. Jozwiak, I. Galan, J. M. Grau, V. Vieira, T. A. Treves, S. Ertan, A. Pujol, S. Blecic, E. M. Zanette, F. Ceriani, W. Camu, L. Aquilone, A. Benomar, F. Greco, A. Pascual-Leone Pascual, T. Yanagihara, F. A. Delfino, R. Damels, S. Merkelbach, J. Beltran, A. Barrientos, S. Brugge, B. Hildebrandt-Müller, M. H. Nascimento, M. Rocchi, F. Cervantes, E. Castelli, R. M. Pressler, S. Yeil, A. del Olmo, J. L. Herranz, L. J. Kappelle, Y. Demir, N. Inoue, R. Hershkoviz, A. Luengo, S. Bien, F. Viallet, P. Malaspina, G. De Michele, G. Nolfe, P. Adeleine, T. Liehr, G. Fenelon, H. Masson, Kailash P. Bhatia, W. Haberbosch, S. Mederer, R. S. J. Frackowiak, Tanya Stojkovic, S. Previtali, A. E. Harding, W. Kohler, N. P. Quin, T. R. Marra, J. P. Moisan, A. Melchor, M. L. Viguera, Mary G. Sweeney, G. L. Romani, J. Hezel, R. A. Dierckx, R. Torta, A. Kratzer, T. Pauwels, D. Decoo, Adriana Campi, Neil Kitchen, J. Haas, U. Neubauer, J. J. Merland, A. Yagiz, A. Antonuzzo, A. Zangaladze, J. Parra, Pablo Martinez-Lage, D. J. Brooks, S. Hauser, R. Di Pierri, M. Campero, R. Caldarelli-Stefano, A. M. Colangelo, J. L. Pozo, C. Estol, F. Picard, A. Palmieri, J. Massons, JT Phillips, G. B. Groozman, R. Pentore, L. M. Ossege, C. Bayon, Hans-Peter Hartung, R. Konyalioglu, R. Lampis, D. Ancri, M. Miletta, F. J. Claramonte, W. Retz, F. Hentges, JM Cooper, M. Cordes, M. Limburg, M. Brock, G. R. Coulton, K. Helmke, Rosa Larumbe, A. Ohly, F. Landgraf, A. M. Drewes, Claudia Trenkwalder, M. Keidel, T. Segura, C. Scholz, J. HÄgele, D. Baudoin-Martin, P. Manganelli, J. Valdueza, M. Farinotti, U. Zwiener, M. P. Schiavalla, Y. P. Young, O. Barlas, G. Hertel, E. H. Weiss, M. Eiselt, A. Lossos, M. Bartoli, L. Krolicki, W. Villafana, W. Peterson, Nicoletta Meucci, C. Agbo, R. Luksch, F. Fiacco, G. Ponsot, M. Lopez, Howard L. Weiner, M. D. Alonso, K. Petry, Sanjay M. Sisodiya, P. Giustini, S. Tyrdal, R. Poupon, J. Blanke, P. Oubary, A. A. Kruize, H. Trabucchi, R. R. C. Stewart, H. Grehl, B. M. Kulig, V. Vinhas, D. Spagnoli, B. Mahe, J. Tatay, C. Hess, M. D. Albadalejo, G. Birbamer, M. Alonso, F. Valldeoriola, J. Figols, I. Wirguin, E. Diez Tejedor, C. S. Weiller, L.H. van den Berg, P. Barreiro, L. Pianese, S. Cocozza, R. Kohnen, E. Redolfi, F. Faralli, G. Gosztonyl, A. J. Gur, A. Keyser, V. Fichter-Gagnepain, B. Wildemann, E. Omodeo-Zorini, Gregoire, J. Schopohl, F. Fraschini, G. Wunderlich, B. Jakubowska, F. P. Serra, N. B. Jensen, O. Delattre, C. Leno, A. Dario, P. Grafe, F. Graus, M. C. Vigliani, J. L. Dobato, Philip N. Hawkins, R. Marés, A. Rimola, N. Meussi, G. Aimard, W. Hospers, A. M. Robertson, C. Kaplan, W. Lamadé, Karen E. Morrison, Amadio, E. Kieffer, F. Dromer, P. Bernasconi, M. Repeto, Davide Pareyson, Jeremy Rees, A. Guarneri, P. Odin, P. Bouche, L. Nogueira, J. Munoz, L. Leocani, M. J. Arcusa, R. S. J. Frackowiack, John S. Duncan, D. Karacostas, D. Edwin, I. Costa, M. Menetrey, P. Grieb, A. M. Salvan, S. Cunha, P. Merel, P. Pfeiffer, A. Astier, F. Federico, A. Mrabet, M. G. Buzzi, L. Knudsen, I. F. Pye, L. Falqui, C. R. Hornig, C. E. Shaw, C. Brigel, T. C. Britton, R. Codoceo, T. Pampols, Vincent J. Cunningham, N. Archidiacono, G. Chazot, J. B. Posner, L. L. O. Befalo, M. Monclus, C. Cabezas, H. Moser, H. Stodal, J. Ley-Pozo, L. Brusa, R. Di Mascio, P. Giannini, J. Fernandez, R. Santiago Luis, J. Garcia Tigera, J. Wilmink, P. Pignatelli, M. El Amrani, V. Lucivero, M. Baiget, R. Lodi, P. H. Cabre, L. Grande, A. Korczyn, R. Fahlbusch, C. Milanese, W. Huber, J. Susseve, H. C. Nahser, K. Mondrup, X. O. Breakefield, J. Sarria, T. H. Vogt, A. Alessandri, M. Daffertshofer, I. Nelson, M. L. Monticelli, O. Dammann, G. G. Farnarier, G. Felisari, A. Quattrini, A. Boiardi, P. Mazetti, H. Liu, J. Duarte, M. E. Gaunt, H. Strik, N. Yulug, A. Urman, J. Posner, Aida Suarez Gonzalez, Ma. L. Giros, Z. Matkovic, D. Kompf, A. D. Korczyn, A. Steinbrecher, R. Wenzel, M. C. de Rijk, R. Doronzo, J. Julien, O. Hasegawa, M. Kramer, V. Collado-Scidel, M. Alonso de Lecinana, L. Dell'Arciprete, S. Rapuzzi, S. Bahar, H. Willison, M. T. Ramacci, J.J. Martin, Lopez-Bresnahan, C. Malapani, R. Haaxma, T. Rosenberg, J. Patrignani, R. Vichi, Martin R. Farlow, J. Roquer, L. Krols, M. Pimenta, C. Bucka, U. Klose, M. Roberts, J. Salas-Puig, R. Ghnassia, A. Mercuri, C. Maltempo, I. Tournev, P. Homeyer, D. Caparros-Lefevre, E. P. O. Sullivan, T. Vashadze, Ph. Lyrer, A. Deltoro, H. Kondo, M. Steinling, A. Graham, G. C. Miescher, A. Pace, D. Branca, G. Avello, H. H. Kornhuber, D. Fernandes, H. Friedrich, R. Chorao, H. O. Lüders, R. T. Bax, J. A. Macias, N. Yilmaz, J. Veroust, M. Miller, S. Confort-Gouny, J. L. Sastre, D. Servello, G. Boysen, S. Koeppen, V. Planté-Bordeneuve, H. Albrecht, R. H. M. King, G. Orkodashili, R. Doornbos, H. Toyooka, V. Larrue, M. Sabatelli, K. Williams, M. Stevens, V. Maria, M. Comabella, C. Lammers, R. M. L. Poublon, E. Tizzano, P. Pazzaglia, F. Zoeller, M. B. Delisle, J. P. Goument, J. M. Minderhoud, A. Sghirlanzoni, V. Meininger, M. Al Deeb, C. Bertelt, A. Cagni, A. Algra, F. Morales, K. A. Flugel, M. Maidani, M. Noya, Z. Seidl, U. Roelcke, D. Cannata, E. Katiane EmbiruÇu, E. M. Wicklein, K. Willmes, L. Hanoglu, J. F. Pellissier, Yves Agid, E. Cuadrado, S. Brock, D. Maimone, Z. G. Nadareishvili, E. Matta, S. Hilmi, V. Assuerus, F. Lomena, R. Springer, F. Cabrera-Valdivia, Oscar L. Lopez, M. Casazza, F. Vivancos, Ralf Gold, T. Crawford, B. Moulard, M. Poisson, W. l. McDonald, D. E. Grobbe, Alan Connelly, H. Ozcan, S. Abeta, H. Severo Ochoa, A. C. van Loenen, E. Libson, M. J. Marti, B. George, C. Ferrarese, B. Jacobs, L. Divano, T. Ben-Hur, A. L. Bootsma, V. Martinez, A. Conti, R. P. Maguire, B. Schmidt, D. M. Campos, D. A. Guzman, E. Meary, C. Richart, P. B. Christensen, T. Schroeder, Massimo Zeviani, K. Jensen, R. Aliaga, S. Seitz-Dertinger, J. W. Griffin, C. Fryze, H. Baas, S. Braun, A. M. Porrini, B. Yemez, M. J. Sedano, C. Creisson, A. Del Santo, A. Mainz, R. Kay, S. Livraghi, R. de Waal, D. Macgregor, H. Hefter, R. Garghentino, U. Ruotsalainen, M. Matsumoto, M. G. Beaudry, P. M. Morrison, J. C. Petit, C. Walon, Ph. Chemouilli, F. Henderson, R. Massa, A. Cruz Martinez, U. Liska, F. Hecht, Ernst Holler, V. S. de Bruin, B. B. Sheitman, S. M. Bentzen, C. Bayindir, F. Pallesta, P. E. Roland, J. Parrilla, P. Zunker, L. F. Burchinskaya, G. Mellino, S. Ben Ayed, D. Bonneau, P. Nowacki, M. Goncalves, P. Riederer, N. Mavroudakis, J. Togores, L. Rozewicz, S. Robeck, Y. Perez Gilabert, L. Rampello, A. Rogopoulos, S. Martinez, F. Schildermans, C. Radder, P. B. Hedlund, J. Cambier, M. Aabed, G. D. Jackson, P. Gasparini, P. Santacruz, J. Vandevivere, H. Dural, A. Mantel, W. Dorndorf, N. Ediboglu, A. Lofgren, J. Bogousslavsky, P. Thierauf, L. Goullard, R. Maserati, B. Moering, M. Ryba, J. Serra, G. G. Govan, A. Pascual-Leone, S. Schaeffer, M. R. Rosenfeld, A. P. Correia, K. Ray Chaudhuri, L. Campbell, R. Spreafico, B. Genetet, A. M. Tantot, R. A. G. Hughes, J. A. Vidal, G. Erkol, J. Y. Delattre, B. Yaqub, B. K. Hecht, E. Mayayo, Ph. Scheltens, J. Corral, M. Calaf, L. Henderson, C. Y. Li, U. Bogdahn, R. Sanchez-Roy, M. Navasa, J. Ballabriga, G. Broggi, T. Gudeva, C. Rose, J. Vion-Dury, J. A. Gastaut, J. Pniewski, Nicola J. Robertson, G. Kohncke, M. Billot, S. Gok, E. Castellli, F. Denktas, P. Bazzi, F. Spinelli, I. F. Moseley, C. D. Mardsen, B. Barbiroli, O. M. Koriech, A. Miller, Hiroaki Yoshikawa, F. X. Borruat, J. Zielasek, P. Le Coz, J. Pascual, A. Drouet, L. T. Giron, F. Schondube, R. Midgard, M. Alizadeh, M. Liguori, Lionel Ginsberg, L. Harms, C. Tilgner, G. Tognoni, F. Molteni, Mar Tintoré, M. Psylla, C. Goulon-Goeau, M. V. Aguilar, Massimo Filippi, K. H. Mauritz, Thomas V. Fernandez, C. Basset, S. Rossi, P. Meneses, B. Jandolo, T. Locatelli, D. Shechtcr, C. Magnani, R. Ferri, Bruno Dubois, J. M. Warier, S. Berges, F. Idiman, M. Schabet, R. R. Diehl, P. D'aurelio, M. Musior, Reinhard Hohlfeld, P. Smeyers, M. Olivé, A. Riva, C. A. Broere, N. Egund, S. Franceschetti, V. Bonavita, Nicola Canal, E. Timmermans, M. Ruiz, S. Barrandon, G. Vasilaski, B. Deweer, L. Galiano, S. F. T. M. de Bruijn, L. Masana, A. Goossens, B. Heye, K. Lauer, Heinz Gregor Wieser, Stephen R. Williams, B. Garavaglia, A. P. Sempere, F. Grigoletto, P. Poindron, R. Lopez-Pajares, I. Leite, T. A. McNell, C. Caucheteur, J. M. Giron, A. D. Collins, P. Freger, J. Sanhez Del Rio, D. A. Harn, K. Lindner, S. S. Scherer, G. Serve, M. Juncadella, X. Estivill, R. Binkhorst, M. Anderson, B. Tekinsoy, C. Sagan, T. Anastopoulos, G. Japaridze, S. Guillou, F. Erminio, Jon Sussman, P. G. Oomes, D. S. Rust, S. Mascheroni, O. Berger, M. Peresson, K. V. Toyka, T. W. Polder, M. Huberman, B. Arpaci, H. Ramtami, I. Martinez, Ph. Violon, P. P. Gazzaniga Pozzill, R. Ruda, P. Auzou, J. Parker, S. P. Morrissey, Jiahong Zhu, F. Rotondi, P. Baron, W. Schmid, P. Doneda, M. Spadaro, M. C. Nargeot, I. Banchs, J.S.P. van den Berg, R. Ferrai, M. Robotti, M. Fredj, Pedro M. Rodríguez Cruz, B. Erne, D. G. Piepgras, M. C. Arne-Bes, J. Escudero, C. Goetz, A. R. Naylor, M. Hallett, O. Abramsky, E. Bonifacio, L. E. Larsson, R. Pellikka, P. Valalentino, D. Guidetti, B. Buchwald, C. H. Lücking, D. Gauvreau, F. Pfaff, A. Ben Younes-Chennoufi, R. Kiefer, R. Massot, K. A. Hossmann, L. Werdelin, P. J. Baxter, U. Ziflo, S. Allaria, C. D. Marsden, M. Cabaret, S. P. Mueller, E. Calabrese, R. Colao, S. I. Bekkelund, M. Yilmaz, O. Oktem-Tanor, R. Gine, M. E. Scheulen, J. Beuuer, A. Melo, Z. Gulay, M. D. Have, C. Frith, D. Liberati, J. Gozlan, P. Rondot, Ch. Brunholzl, M. Pocchiari, J. Pena, L. Moiola, C. Salvadori, A. Cabello, T. Catarci, S. Webb, C. Dettmers, N. A. Gregson, Alexandra Durr, F. Iglesias, U. Knorr, L. Ferrini-Strambi, F. Kruggel, P. Allard, A. Coquerel, P. Genet, F. Vinuels, C. Oberwittler, A. Torbicki, P. Leffers, B. Renault, B. Fauser, C. Ciano, G. Uziel, J. M. Gibson, F. Anaya, C. Derouesné, C. N. Anagnostou, M. Kaido, W. Eickhoff, G. Talerico, M. L. Berthier, A. Capdevila, M. Alons, D. Rezek, E. Wondrusch, U. Kauerz, D. Mateo, M. A. Chornet, Holon, N. Pinsard, I. Doganer, E. Paoino, H. Strenge, C. Diaz, J. R. Brasic, W. Heide, I. Santilli, W. M. Korn, D. Selcuki, M. J. Barrett, D. Krieger, T. Leon, T. Houallah, M. Tournilhac, C. Nos, D. Chavot, F. Barbieri, F. J. Jimenez-Jimenez, J. Muruzabal, K. Poeck, A. Sennlaub, L. M. Iriarte, L. G. Lazzarino, C. Sanz, P. A. Fischer, S. D. Shorvon, R. Hoermann, F. Delecluse, M. Krams, O. Corabianu, F. H. Hochberg, Christopher J. Mathias, B. Debachy, C. M. Poser, L. Delodovici, A. Jimenez-Escrig, F. Baruzzi, F. Godenberg, D. Cucinotta, P. J. Garcia Ruiz, K. Maier-Hauff, P. R. Bar, R. Mezt, R. Jochens, S. Karakaneva, C. Roberti, E. Caballero, Joseph E. Parisi, M. Zamboni, T. Lacasa, B. Baklan, J. C. Gautier, J. A. Martinez-Matos, W. Pollmann, G. Thomas, L. Verze, E. Chleide, R. Alvarez Sala, I. Noel, E. Albuisson, O. Kastrup, S. I. Rapoport, H. J. Braune, H. Lörler, M. Le Merrer, A. Biraben, S. Soler, S. J. Taagholt, U. Meyding-Lamadé, K. Bleasdale-Barr, Isabella Moroni, Y. Campos, J. Matias-Guiu, G. Edan, M. G. Bousser, John B. Clark, J. Garcia de Yebenes, N. K. Olsen, P. Hitzenberger, S. Einius, Aj Thompson, Ch. J. Vecht, T. Crepin-Leblond, Klaus L. Leenders, A. Di Muzio, L. Georgieva, René Spiegel, K. Sabey, D. Ménégalli, J. Meulstee, U. Liszka, P. Giral, C. Sunol, J. M. Espadaler, A. D. Crockar, K. Varli, G. Giraud, P. J. Hülser, A. Benazzouz, A. Reggio, M. Salvatore, K. Genc, M. Kushnir, S. Barbieri, J. Ph. Azulay, M. Gianelli, N. Bathien, A. AlMemar, F. Hentati, I. Ragueneau, F. Chiarotti, R. C. F. Smits, A. K. Asbury, F. Lacruz, B. Muller, Alan J. Thompson, Gordon Smith, K. Schmidt, C. Daems Monpeun, Juergen Weber, A. Arboix, G. R. Fink, A. M. Cobo, M. Ait Kaci Ahmed, E. Gencheva, Israel-Biet, G. Schlaug, P. De Jonghe, Philip Scheltens, K. Toyka, P. Gonzalez-Porque, A. Cila, J. M. Fernandez, P. Augustin, J. Siclia, S. Medaglini, D. E. Ziogas, A. Feve, L. Kater, G. J. E. Rinkel, D. Leppert, Rüdiger J. Seitz, S. Ried, C. Turc-Carel, G. Smeyers, F. Godinho, M. Czygan, M. Rijntjes, E. Aversa, M. Frigo, Leif Østergaard, J. L. Munoz Blanco, A. Cruz-Matinez, J. De Reuck, C. Theillet, T. Barroso, V. Oikonen, Florence Lebert, M. Kilinc, C. Cordon-Cardon, G. Stoll, E. Thiery, F. Pulcinelli, J. Solski, M. Schmiegelow, L. J. Polman, P. Fernandez-Calle, C. Wikkelso, M. Ben Hamida, M. Laska, E. Kott, W. Sulkowski, C. Lucas, N. M. Bornstein, D. Schmitz, M. W. Lammers, A. de Louw, R. J. S. Wise, P. A. van Darn, C. Antozzi, P. Villanueva, P. H. E. Hilkens, C. Constantin, W. Ricart, A. Wolf, M. Gamba, P. Maguire, Alessandro Padovani, B. M. Patten, Marie Sarazin, H. Ackermann, L. Durelli, S. Timsit, Sebastian Jander, B. W. Scheithauer, G. Demir, J. P. Neau, P. Barbanti, A. Brand, N. AraÇ, V. Fischer-Gagnepain, R. Marchioli, G. Serratrice, C. Maugard-Louboutin, G. T. Spencer, D. Lücke, G. Mainardi, K. Harmant Van Rijckevorsel, G. B. Creel, R. Manzanares, Francesco Fortunato, A. May, J. Workman, K. Johkura, E. Fernandez, Carlo Colosimo, L. Calliauw, L. Bet, Félix F. Cruz-Sánchez, M. Dhib, H. Meinardi, F. Carrara, J. Kuehnen, C. Peiro, H. Lassmann, K. Skovgaard Olsen, A. McDonald, L. Sciulli, A. Cobo, A. Monticelli, B. Conrad, J. Bagunya, J. Benitez, V. Desnizza, B. Dupont, O. Delrieu, D. Moraes, J. J. Heimans, F. Garcia Rio, M. Matsumto, A. Fernandez, R. Nermni, R. Chalmers, M. J. Marchau, F. Aguado, P. Velupillai, P. J. Martin, P. Tassan, V. Demarin, A. Engelien, T. Gerriets, Comar, J. L. Carrasco, J. P. Pruvo, A. Lopez de Munain, D. Pavitt, J. Alarcon, Chris H. Polman, B. Guldin, N. Yeni, Hartmut Brückmann, N. Wilczak, H. Szwed, R. Causaran, G. Kyriazis, M. E. Westarp, M. Gasparini, N. Pecora, J. M. Roda, E. Lang, V. Scaioli, David R. Fish, D. Caputo, O. Gratzl, R. Mercelis, A. Perretti, G. Steimetz, I. Link, C. Rigoletto, A. Catafau, G. Lucotte, M. Buti, G. Fagiolari, A. Piqueras, C. Godinot, J. C. Meurice, Erodriguez J. Dominigo, F. Lionnet, H. Grzelec, David J. Brooks, P. M. G. Munro, F. X. Weilbach, M. Maiwald, W. Split, B. Widjaja-Cramer, V. Ozturk, J. Colas, E. Brizioli, J. Calleja, L. Publio, M. Desi, R. Soffietti, P. Cortinovis-Tourniaire, E. F. Gonano, G. Cavaletti, S. Uselli, K. Westerlind, H. Betuel, C. O. Dhiver, H. Guggenheim, M. Hamon, R. Fazio, P. Lehikoinen, A. Esser, B. Sadzot, G. Fink, Angelo Antonini, D. Bendahan, V. Di Carlo, G. Galardi, A. F. Boller, M. Aksenova, Del Fiore, V. de la Sayette, H. Chabriat, A. Nicoletti, A. Dilouya, M. L. Harpin, E. Rouillet, J. Stam, A. Wolters, M. R. Delgado, Eduardo Tolosa, G. Said, A. J. Lees, L. Rinaldi, A. Schulze-Bonhage, MA Ron, C. Lefebvre, E. W. Radü, R. Alvarez, M. L. Bots, P. Reganati, S. Palazzi, A. Poggi, N. J. Scolding, V. Sazdovitch, T. Moreau, E. Maes, M. A. Estelies, P. Petkova, Jose-Felix Marti-Masso, G De La Meilleure, N. Mullatti, M. Rodegher, N. C. Notermans, T. A. T. Warner, S. Aktan, J. P. Louboutin, L. Volpe, C. Scheidt, W. Aust, C. M. Wiles, U. Schneider, S. K. Braekken, W. R. Willems, K. Usuku, Peter M. Rothwell, C. Talamon, M. L. Sacchetti, A. Codina, M. H. Marion, A. Santoro, J. Roda, A. Bordoni, D. J. Taylor, S. Ertas, H. H. Emmen, J. Vichez, V. BesanÇon, R. E. Passingham, M. L. Malosio, A. Vérier, M. Bamberg, A. W. Hansen, E. Mostacero, G. Gaudriault, Marie Vidailhet, B. Birebent, K. Strijckmans, F. Giannini, T. Kammer, I. Araujo, J. Nowicki, E. Nikolov, A. Hutzelmann, R. Gherardi, J. Verroust, L. Austoni, A. Scheller, A. Vazquez, S. Matheron, H. Holthausen, J. M. Gerard, M. Bataillard, S. Dethy, V. H. Patterson, V. Ivanez, N. P. Hirsch, F. Ozer, M. Sutter, C. Jacomet, M. Mora, Bruno Colombo, A. Sarropoulos, T. H. Papapetropoulos, M. Schwarz, D. S. Dinner, N. Acarin, B. Iandolo, J. O. Riis, P. R. J. Barnes, F. Taroni, J. Kazenwadel, L. Torre, A. Lugaresi, I. L. Henriques, S. Pauli, S. Alfonso, Pedro Quesada, A. S. T. Planting, J. M. Castilla, Thomas Gasser, M. Van der Linden, A. Alfaro, E. Nobile-Orazio, G. Popova, W. Vaalburg, F. G. A. van der Mech, L. Williams, F. Medina, J. P. Vernant, J. Yaouanq, B. Storch-Hagenlocher, A. Potemkowski, R. Riva, M. H. Mahagne, M. Ozturk, Ve. Drory, N. Konic, C. Jungreis, A. Pou Serradell, J. L. Gauvrit, G. J. Chelune, S. Hermandez, T. Dingus, L. Hewer, Ch. Koch, M. N. Metz-Lutz, G. Parlato, M. Sinaki, Charles Pierrot-Deseilligny, H. C. Diener, J. Broeckx, J. Weill-Fulazza, M. L. Villar, M. Rizzo, O. Ganslandt, C. Duran, N. A. Fletcher, G. Di Giovacchino, Susan T. Iannaccone, C. Kolig, N. Fabre, H. A. Crockard, Rita Bella, M. Tazir, E. Papagiannuli, K. Overgaard, Emma Ciafaloni, I. Lorenzetti, F. Viader, P. A. H. Millac, I. Montiel, L. H. Visser, M. Palomar, P. L. Murgia, H. Pedersen, Rafael Blesa, S. Seddigh, W. O. Renier, I. Lemahieu, H. M. L. Jansen, L. Rosin, J. Galofre, K. Mattos, M. Pondal, G. M. Hadjigeorgiou, D. Francis, L. Cantin, D. Stegeman, M. Rango, A. B. M. F. Karim, S. Schraff, B. Castellotti, I. Iriarte, E. Laborde, T. J. Tjan, R. Mutani, D. Toni, B. Bergaasco, J. G. Young, C. Klotzsch, A. Zincone, X. Ducrocq, M. Uchuya, O. J. Kolar, A. Quattrone, T. Bauermann, Nereo Bresolin, J. Vallée, B. C. Jacobs, A. Campos, Werner Poewe, J. A. Villanueva, A. W. Kornhuber, A. Malafosse, E. Diez-Tejedor, G. Jungreia, M. J. A. Puchner, A. Komiyama, O. Saribas, V. Volpini, L. Geremia, S. Bressi, A. Nibbio, Timothy E. Bates, T. z. Tzonev, E. Ideman, G. A. Damlacik, G. Martino, G. Crepaldi, T. Martino, Kjell Någren, E. Idiman, D. Samuel, J. M. Perez Trullen, Y. van der Graaf, J. O. Thorell, M. J. M. Dupuis, E. Sieber, R. D'Alessandro, C. Cazzaniga, J. Faiss, A. Tanguy, A. Schick, I. Hoksergen, A. Cardozo, R. Shakarishvili, G. K. Wennlng, J. L. Marti-Vilalta, J. Weissenbach, I. L. Simone, Amalia C. Bruni, Darius J. Adams, C. Weiller, A. Pietrangeli, F. Croria, C. Vigo-Pelfrey, Patricia Limousin, A. Ducros, G. Conti, O. Lindvall, E. Richter, M. Zuffi, A. Nappo, T. Riise, J. Wijdenes, M. J. Fernandez, J. Rosell, P. Vermersh, S. Servidei, M. S. C. Verdugo, F. Gouttiere, W. Solbach, M. Malbezin, I. S. Watanabe, A. Tumac, W. I. McDonald, D. A. Butterfield, P. P. Costa, F. deRino, F. Bamonti, J. M. Cesar, C. H. Lahoz, I. Mosely, M. Starck, M. H. Lemaitre, K. M. Stephan, S. Tex, R. Bokonjic, I. Mollee, L. Pastena, M. Gutierrez, F. Boiler, M. C. Martinez-Para, M. Velicogna, O. Obuz, A. Grinspan, M. Guarino, L. M. Cartier, E. Ruiz, D. Gambi, S. Messina, M. Villa, Michael G. Hanna, J. Valk, Leone Pascual, M. Clanet, Z. Argov, B. Ryniewicz, E. Magni, B. Berlanga, K. S. Wong, C. Gellera, C. Prevost, F. Gonzalez-Huix, R. Petraroli, J. E. G. Benedikz, I. Kojder, C. Bommelaer, L. Perusse, M. R. Bangioanni, Guy M. McKhann, A. Molina, C. Fresquet, E. Sindern, Florence Pasquier, M. J. Rosas, M. Altieri, O. Simoncini, M. Koutroumanidis, C. A. F. Tulleken, M. Dary-Auriol, S. Oueslati, H. Kruyer, I. Nishisho, C. R. Horning, A. Vital, G. V. Czettritz, J. Ph. Neau, B. Mihout, A. Ameri, M. Francis, S. Quasthoff, D. Taussig, S. Blunt, P. Valentin, C. Y. Gao, O. Heinzlef, H. d'Allens, C. Coudero, M. Erfas, G. Borghero, P. J. Modrego Pardo, M. C. Patrosso, N. L. Gershfeld, P. A. J. M. Boon, O. Sabouraud, M. Lara, J. Svennevig, G. L. Lenzi, A. Barrio, H. Villaroya, JosÇ M. Manubens, O. Boespflug-Tanguy, M. Carreras, D. A. Costiga, J. P. Breux, S. Lynn, C. Oliveras Ley, A. G. Herbaut, J. Nos, C. Tornali, Y. A. Hekster, J. L. Chopard, J. M. Manubens, P. Chemouilli, A. Jovicic, F. Dworzak, S. Smirne, S. E. Soudain, B. Gallano, D. Lubach, G. Masullo, G. Izquierdo, A. Pascual Leone Pascual, A. Sessa, V. Freitas, O. Crambes, L. Ouss, G. W. Van Dijk, P. Marchettini, P. Confalonieri, M. Donaghy, A. Munnich, M. Corbo, and M. E. L. van der Burg
Subjects: Neurology, business.industry, Media studies, Library science, Medicine, Neurology (clinical), business
Published: 1994

33. Reasons why therapeutic apheresis should belong to nephrology

Author: F, Anaya Fernández-Lomana
Subjects: Male, Pregnancy, Humans, Female, Plasmapheresis
Published: 2011

34. Treatment of acute antibody-mediated rejection: a single-center experience

Author: F. Anaya, M. Rodríguez Ferrero, L. Bucalo, A. Rincón, and A. Rementería
Subjects: Adult, Graft Rejection, Male, medicine.medical_specialty, medicine.medical_treatment, Urology, Renal function, Azathioprine, Antibodies, Antibodies, Monoclonal, Murine-Derived, medicine, Humans, Kidney transplantation, Transplantation, business.industry, Immunoglobulins, Intravenous, Immunosuppression, Plasmapheresis, Middle Aged, medicine.disease, Kidney Transplantation, Tacrolimus, Surgery, Creatinine, Rituximab, Female, business, Immunosuppressive Agents, medicine.drug
Abstract: Introduction Acute antibody-mediated rejection (AMR) leads to graft loss. The combination of plasmapheresis (PP), intravenous immunoglobulin (IVIG), and rituximab (RTX) has been reported to be effective therapy. Patients and methods Between October 2005 and September 2009, 8 (4.7%) kidney transplant recipients developed AMR, diagnosed by severe acute rejection and extensive C4d staining in peritubular capillaries. Results All patients were treated with two to six sessions of PP with IVIG added after the last PP. In two patients, RTX was prescribed after PP and IVIG. Baseline immunosuppression was based on steroids, mycophenolate mofetil or azathioprine, and tacrolimus or cyclosporine or everolimus. The presence of subsequent significant decrease in anti-HLA class I antibodies was demonstrated in a highly sensitized patient before and after transplantation with PP treatment. An increase was observed before the diagnosis of AMR. After a mean follow-up of 10 months (range = 1–23), patient and graft survivals were 100% and 50%, respectively. Three patients lost their transplants to AMR refractory to treatment and one patient, due to interstitial fibrosis and tubular atrophy at 23 months after AMR. Finally, four patients recovered renal function, showing a mean serum creatinine of 2.2 ± 0.45 mg/dL. Conclusions Early diagnosis and treatment with PP, IVIG, and RTX may resolve AMR. PP before and after transplantation in high-risk patients may result in anti-HLA class I and class II antibody removal from plasma and prevention of AMR.
Published: 2010

35. Insights into Entamoeba histolytica virulence modulation

Author: F Padilla-Vaca and F Anaya-Velázquez
Subjects: Microbiology (medical), Proteases, Virulence Factors, Mutant, Virulence, medicine.disease_cause, Virulence factor, Entamoeba, Entamoeba histolytica, Species Specificity, parasitic diseases, medicine, Humans, Pharmacology, Genetics, Mutation, biology, Entamoebiasis, General Medicine, biology.organism_classification, Phenotype, Molecular Medicine, Adaptation
Abstract: Entamoeba histolytica is able to invade human tissues by means of several molecules and biological properties related to the virulence. Pathogenic amebas use three major virulence factors, Gal/GalNAc lectin, amebapore and proteases, for lyse, phagocytose, kill and destroy a variety of cells and tissues in the host. Responses of the parasite to host components such as mucins and bacterial flora influence the behavior of pathogenic amebas altering their expression of virulence factors. The relative virulence of different strains of E. histolytica has been shown to vary as a consequence of changes in conditions of in vitro cultivation which implies substantial changes in basic metabolic aspects and factors directly and indirectly related to amebic virulence. Comparison of E. histolytica strains with different virulence phenotypes and under different conditions of growth will help to identify new virulence factor candidates and define the interplay between virulence factors and invasive phenotype. Virulence attenuate mutants of E. histolytica are useful also to uncover novel virulence determinants. The comparison of biological properties and virulence factors between E. histolytica and E. dispar, a non-pathogenic species, has been a useful approach to investigate the key factors involved in the experimental presentation of amebiasis and its complex regulation. The molecular mechanisms that regulate these variations in virulence are not yet known. Their elucidation will help us to better understand the gene expression plasticity that enables the effective adaptation of the ameba to changes in growth culture conditions and host factors.
Published: 2009

36. Contents, Vol. 58, 1991

Author: Z.H. Endre, Lawrence S. Milner, F. Lemercier, Susanne Horner, Yuji Nagura, P. Saiag, Kazuro Kanatsu, G.A. Balderson, Nachman Brautbar, Takahiko Ono, Franz Fazekas, Atul T. Roy, M.C. de Vernejoul, Tateki Kitaoka, Ove Noren, Geoffrey H. Cope, Xi-Xiong Kang, Michèle Kessler, Batya Kristal, S.L. Lynch, Toshio Doi, Wolfgang Freidl, M.H. Gault, D.H.G. Crawford, Hans Sjöström, M. Potiron-Josse, Masami Kozaki, R. Korte, Jörg H. Horina, Chika Onoe, Yasuhiko Ito, H. Longerich, Kazutomo Ujiie, Mark T. Houser, J.D. Ginet, Helmut Pogglitsch, Nicholas D. Slater, O. Jovanović, A. Quoidbach, Masaharu Yoshida, S.J. Fleming, C.G.H. Maidment, P.C.K. Chan, H. Demol, I. Lubrich-Birkner, H.B. Steinhauer, Monique Elseviers, Luiz C. Cintra, Tamar Shkolnik, M. Kostić, Marc E. De Broe, P. Schollmeyer, Frank L. Van de Vyver, Paulo Sérgio Medeiros dos Santos, Y. Pirson, Takashi Suzuki, Guy D. Nuyts, Eri Muso, Norio Kaji, L. Longerich, Tadao Akizawa, Kazuyoshi Okada, Hiroyuki Nagai, Franz Payer, Osnat Steinberger, K.W. Chan, Atsushi Fukatsu, Hanns M. Winkler, Ronny A. Daelemans, Michinobu Hatano, D. Le Carrer, P. Galle, P. Bindi, Hirofumi Tamai, Tohru Tamaki, Kazuhiro Nishikawa, Bruno Hurault de Ligny, Wahei Matsukawa, Patrick C. D'Haese, Ab. Akosa, Guenter J. Krejs, Heinz Valetitsch, T.M. Chan, Andrew T. Raftery, Niembro De Rasche, M.A. Rengel, Mamoru Maejima, Chuichi Kawai, R. Khayat, Martin Magnusson, Anna Galar, Eriko Kinugasa, B. Winterberg, Uri Shasha, Roberto Silva Costa, Shaul M. Shasha, Etsuo Sakurai, Michael Slater, P. Gris, Futoshi Yoshida, Gomez Campdera, Tatsuto Kimachi, M. Popović-Rolović, Akira Owada, Torsten Denneberg, Nils-Georg Asp, Marie C. Béné, Kimio Tomita, H.P. Bertram, Noriaki Matsui, Hidekazu Shigematsu, Agenor Spallini Ferraz, Gilbert C. Faure, Shozo Koshikawa, Tadao Tamura, Sverker Eneström, J.-P. Vaerman, Maria Walczuk, Stanislaw Jankowski, David B. N. Lee, V.L.M. Esnault, D. Popović, Toshihiko Hirano, Philippe G. Jorens, F. Anaya, Susumu Takahashi, A. Testa, Kryspina Grzybek-Hryncewicz, Satoshi Sekiyama, Haruyoshi Yoshida, Mitsuru Yanai, A. Antić-Peco, Seiichi Matsuo, J. Hamels, Miriam Barzilai, B. Viron, I.K.P. Cheng, Fumiaki Marumo, Vanda Jorgetti, Márcio Dantas, F. Valderrabano, R.A. Axelsen, J. Guenel, Kitaro Oka, A. Galan, A. Sherif, Kenichi Sekita, I. Keck, Kurt Niederkorn, and N.R. Robles
Subjects: Traditional medicine, business.industry, Medicine, business
Published: 1991

37. Renal transplantation in the modern immunosuppressive era in Spain: four-year results from a multicenter database focus on post-transplant cardiovascular disease

Author: Salvador Gil Vernet, L. Capdevila, Manuel Arias, Luis M Pallardó, F. Anaya, Fernando Escuin, Josep M. Campistol, Domingo del Castillo, José M. Morales, Francisco Valdés, Federico Oppenheimer, Jesus Bustamante, Mercedes Cabello, Amado Andrés, D. Serón, Roberto Marcén, Ildefonso Lampreave, and Miguel Gonzalez Molina
Subjects: Adult, Graft Rejection, Male, medicine.medical_specialty, Cardiovascular, Aparato - Enfermedades, Riñones - Trasplante, medicine.medical_treatment, Population, 3205.01 Cardiología, Kaplan-Meier Estimate, Tacrolimus, Chronic allograft nephropathy, Risk Factors, Internal medicine, Medicine, Humans, Longitudinal Studies, Prospective Studies, education, Dialysis, Acute tubular necrosis, Cause of death, education.field_of_study, 3205.06 Nefrología, business.industry, Graft Survival, Middle Aged, Mycophenolic Acid, medicine.disease, Comorbidity, Kidney Transplantation, Surgery, Transplantation, Isquemia, Nephrology, Cardiovascular Diseases, Spain, Mortalidad, Female, Kidney Diseases, business, Immunosuppressive Agents
Abstract: Producción Científica, To evaluate cardiovascular disease (CVD) after renal transplantation we established a CVD database (no-intervention) including all patients transplanted among 2000–2002 in 14 hospitals from Spain (Renal Forum Group) (n¼2600). They were prospective followed annually thereafter and we present herein the most important results concerning survival figures and CVD at four years. Mean recipient age was 49.7±13.7 years: 16% retransplanted and 12.5% hyperimmunized. Tacrolimus, mycophenolate mofetil, and steroids was used in 63%. Acute rejection (AR) rate at 1 year was 14.8%. Graft and patient survival at 48 months were 85.6% (death censored) and 91.7% respectively. The first cause of graft loss was vascular in the first year, death with function during the 2–3 years, and chronic allograft nephropathy at the 4th year. Donor age, time on dialysis, acute tubular necrosis (ATN), AR, SCr at 6 months, the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in the first year, and systolic blood pressure at 24 months were independent risk factors for graft loss at 4th year. The first cause of death was CVD (predominantly ischemic heart disease (IHD) in the first year). Recipient age, ATN, and SCr at 6 months were independent predictors of mortality. Despite worsening of donor age, comorbidity, and advanced age of recipients, survival figures at four years are considered good in our Spanish non-selected population. Cardiovascular mortality is the most important cause of death and graft loss particularly, IHD in the first year. Therefore, to decrease post-transplant mortality a careful cardiovascular evaluation and treatment in the waiting list and a close follow-up of patients after transplantation is mandatory.
Published: 2008

38. Ezetimibe in the treatment of uncontrolled hyperlipidemia in kidney transplant patients

Author: M.L. Rodríguez-Ferrero and F. Anaya
Subjects: Adult, Male, Reoperation, medicine.medical_specialty, Statin, Combination therapy, medicine.drug_class, Renal function, Hyperlipidemias, Kidney Function Tests, Gastroenterology, Ezetimibe, Liver Function Tests, Interquartile range, Internal medicine, Hyperlipidemia, medicine, Humans, Triglycerides, Aged, Transplantation, business.industry, Anticholesteremic Agents, Cholesterol, LDL, Middle Aged, medicine.disease, Kidney Transplantation, Lipids, Surgery, Cholesterol, Azetidines, lipids (amino acids, peptides, and proteins), Drug Therapy, Combination, Female, Liver function, business, Dyslipidemia, Immunosuppressive Agents, medicine.drug
Abstract: Dyslipidemia is an important complication affecting kidney transplant recipients. Statins, the first-line therapy, are often insufficient. Ezetimibe may be effective in combination with statin therapy. We performed a retrospective study to determine the safety and efficacy of ezetimibe treatment in addition to statin therapy among 27 stable renal transplant patients with uncontrolled hypercholesterolemia. We obtained fasting lipid profiles at 3 and 6 months before ezetimibe therapy, while the patients were receiving statins at maximum tolerated doses. Statin doses were stable during the study. All patients received ezetimibe (10 mg) once daily. Fasting lipid profile, kidney function, liver enzymes, creatine kinase, and immunosuppressive drug levels were obtained at baseline as well as at 3 and 6 months post-ezetimibe initiation. Combination therapy resulted in median reductions in total cholesterol of 29% (interquartile range [IQR] 12-39; P = .0001) and 28% (IQR 9-38; P = .0001); in low-density lipoprotein cholesterol of 34% (IQR 16-61; P = .0001) and 44% (IQR 24-56; P = .0001); and in triglycerides of 14% (IQR 4-31; P = .01) and 19% (IQR 1-37; P = .006) at 3 and 6 months post-ezetimibe therapy, respectively. There were no significant differences in high-density lipoprotein cholesterol, renal function, proteinuria, creatine kinase, amylase, liver function, body mass index, or drug levels. There were no adverse drug reactions that mandated treatment withdrawal. When combined with statin therapy ezetimibe seemed to be a safe and effective treatment for uncontrolled dyslipidemia among renal transplant patients.
Published: 2007

39. [Tansitional vesical cell carcinoma metastatizing to the sphenoid sinus]

Author: J M, Molina Ruiz del Portal, F, Anaya, E, Solis, J, Segura, A, Robles, and J M, Castilla
Subjects: Male, Carcinoma, Transitional Cell, Fatal Outcome, Sphenoid Sinus, Urinary Bladder Neoplasms, Biopsy, Humans, Neoplasms, Second Primary, Tomography, X-Ray Computed, Paranasal Sinus Neoplasms, Aged, Neoplasm Staging
Abstract: Secundary tumors of the paranasal sinus are very uncommon with only one hundred cases reported in the literature up to 2001. The commonest site of the primary tumor is the kidney. The maxillary sinus is most often involved. The Sphenoid sinus is the rarest site. We report a rare case of metastasis to the sphenoid sinces from a transitional cell bladder tumor in a 69-year-old man who died after treatment with chemotherapy and we also review the liteature.
Published: 2006

40. [Disseminated cryptococosis in renal transplant recipient]

Author: L, Fernández Rodriguez, R, Amann, E, Verde, M, Ortega, and F, Anaya
Subjects: Adult, Humans, Female, Cryptococcosis, Kidney Transplantation
Abstract: The incidence of cryptococosis ranges from 0.4-5.8% in renal transplant. Meningitis is the principal clinical manifestation, frequently with a subacute curse. In renal transplantation recipients, disseminated cryptococcosis appears as the more frequent presentation. We report a case of a 32 years old woman renal transplant recipient who presents altered mental status, headache and tremor during the month before her assessment to our hospital. Microbiological study was performed in cerebrospinal fluid and cryptococcus was isolated. She was treated with amphotericin B and 5 flucytosine. She developed refractory increased intracranial pressure and a lumboperitoneal derivation was necessary. Cryptococcosis must be considered as cause of meningitis in patients with renal transplant. The early diagnosis and treatment are fundamental due to high mortality of this pathology.
Published: 2005

41. [Localized prostate cancer treatment in renal transplant patient with high intensity focalized ultrasound (HIFU)]

Author: E, Lledó García, J, Jara Rascón, J Ma, Díez Cordero, D, Subirá Ríos, A, Alvarado, F Anaya, Fernández de Lomana, and C, Hernández Fernández
Subjects: Male, Treatment Outcome, Biopsy, Needle, Prostate, Transurethral Resection of Prostate, Humans, Prostatic Neoplasms, Postoperative Period, Adenocarcinoma, Middle Aged, Kidney Transplantation, Ultrasound, High-Intensity Focused, Transrectal, Ultrasonography
Abstract: We report a 62 years old kidney transplant (KT) patient who was diagnosed of localized prostatic cancer (PC) after 6 years of the implant. Transrectal prostatic High Intensity Focused Ultrasound (HIFU) was applied. Results have been satisfactory, achieving pathologic and biochemical success. The discharge was completed at 24 hs, the morbidity was minimal. We have not found any reference in the literature on the appliance of HIFU in PC KT patients. We think that HIFU may represent a good alternative for these patients.
Published: 2005

42. Subject Index Vol. 72, 1996

Author: P. Fardelone, Naoko Yusa, Hirokazu Okada, J. Gondry, N. Seyrek, Hiroshi Mabuchi, D Di Landro, Michihiro Gotoh, Patricia A. Gabow, Per Kjellstrand, Ichiro Koni, Osamu Hotta, Naoyuki Tamura, Hiroshi Toma, Stephen V. Foster, Julio Ramos, V. Bonomini, M. Andréjak, Nilwarangkur S, Stawomir C. Zmonarski, Somkiat Vasuvattakul, Ikuo Horigome, Hidehiko Kawato, L. Raffaele, Toshio Okada, Satoshi Iwabuchi, Keitaro Yokoyama, Neslihan Seyrek, Masateru Kawabata, Yahya Sagliker, Seunghun Lee, Yung-Ming Chen, D. Toncheva, P. Finielz, Kennichi Shiroto, M. Zompatori, Yong Goo Kim, Masaaki Nakayama, M. Crepaldi, Yoshindo Kawaguchi, Yoshiharu Hiratsuka, L. Neri, I. Cheong, Eiko Suzuki, A. Michault, V. Dalmastri, R. Margreiter, Shinsuke Nomura, R. Makdassi, Maria Golato, Kosuke Ota, Scott J. Savader, R. Mallmann, Maria José Panadés, M.S. Garcia de Vinuesa, Hiroshi Osawa, Wadi N. Suki, Yoshiaki Fujimiya, M. Vedovato, T. Dimitrov, Sigeko Hara, Emine Kocabaş, Akpolat Tekin, M. Avramović, Der-Cherng Tarng, A. Giudicissi, Fumihiko Hinoshita, Chih-Wei Yang, Yoshio Suzuki, Regina R. Verani, H. Sonnenberg, Takao Kohsaka, Watanachai Susaengrat, Hiromichi Suzuki, F. Malacarne, Tsutomu Takahashi, Prida Malasit, Chie Inoue, Kandemir Tolga, Lorenzo A. Calò, F. Locatelli, Tun-Jun Tsai, Han-Nan Liu, Augusto Antonello, David J. Leehey, A. Fournier, Mercè Borràs, PeterMaria Rob, F. Zhang, F. Fabrizi, E. De Paoli Vitali, Masami Matsumura, Juan M. Gonzalez, Salih Hazar, J. Guiserix, Raja I. Zabaneh, M. Kostić, George Moustakas, Syunji Ishihara, Chul Woo Yang, B. Athmani, Salvatore Cantaro, Rainer Nobiling, D. Oefner, P. Gilli, Kogo Onodera, Chege J. Mukuria, Y. Sagliker, Vivette D. D'Agati, Shigeo Takebayashi, Hans-Georg Classen, Phannee Pidetcha, M. Hattori, G. Paunović, G.K. Richards, P. Dennis DePalma, Todd S. Ing, Catherine I. Lai, Angela D'Angelo, Hiroshi Kitamura, Zhi-Hong Liu, F. Anaya, Hisashi Ozasa, Mitsuaki Kaizuka, Byung Kee Bang, Christos Iatrou, V. Parezanović, Yoshiko Fujita, G.F. Romagnoli, Mario Liani, Makoto Katagiri, Theodore P. Labus, David P. Brooks, Majed Odeh, Masaru Nasu, Koji Kawamura, A. Peco-Antić, Tanekazu Harada, Kosaku Nitta, Nobuhide Mimura, Liliane J. Striker, I. Guarnori, Syuko Yamamoto, Gengo Osawa, Arturo Borsatti, Ann M. Johnson, Zensuke Ota, Filippo Salvati, Alex W. Yu, Hirofumi Makino, Takao Saruta, Richard Skroeder, Divyesh M. Bhatt, G. Ricci, Masaki Kobayashi, C. Raimondi, L.P.W.J. van den Heuvel, Akira Yamada, C. Aichberger, Young Ok Kim, Kamberi Perparim, Youji Ogawa, Chairat Shayakul, P. Fievet, Hikaru Sugimoto, Necmi Aksaray, D. Marcelli, Osamu Sakai, Ulf Nilsson, Huan-Sheng Chen, Shigeru Horita, Björn Holmquist, Naoto Yamaguchi, E. Lobjoie, Steven Foster, L. Perini, G. Guerra, M. Gowrishankar, Masaharu Naiki, Luan D. Truong, Ank Nurol, Haruki Nagahana, A.F. van Lieburg, Mohamed A. El-Shahawy, Merit F. Gadallah, Hiroshi Inuma, Kaoru Sakai, Kenichi Shikata, Shuichi Tomisawa, Je Hoon Lee, Ching-Huai Huang, Miwako Arai, S. Di Filippo, Stanistaw Miękisz, Constantinos A. Demopoulos, Kouichi Hirayama, R.F. Gagnon, Nobuo Watanabe, G. Pontoriero, Adam Bahattin, Roberto Barrios, P. Vaillant, Makoto Uchiyama, Hiroshi Ishida, Mark W. Majesky, A.G. Brox, G. Erba, Tung-Po Huang, E. Sestigiani, Tadashi Asami, Kunimasa Yan, R. Pérez-García, M. Ramdane, Yoshio Taguma, Yukiyoshi Nakamura, C. Campieri, Shaul G. Massry, Scott O. Trerotola, Satsuki Yamada, Yasuo Magari, Yoshihiko Kanno, S. Paydas, Jana Pindur, L.M. Ho, Peter Nilsson-Ehle, Smaragdi Antonopoulou, W. Proesmans, J. Radivojević, H.A. Jalil, Yu-Li Cho, Ettore Tresca, V.V.A.M. Knoers, Ryokichi Yasumori, J.P. Mallie, Jackson Joe Yium, Byung Kee Kim, Paritosh Tiwari, Kyoko Kurose, V. Stojanov, Hiroyoshi Matsukura, J.M. Hoarau, Silvana Favaro, Bedir Abdülkerim, Hitoshi Ebata, Yuki Sakai, Hiroaki Muramoto, Andrzej Teisseyre, G. Bacchini, Klaus Sack, E. David, I. Constant, F. Valderrábano, Monica Rizzolo, Katsuhiko Sudo, Yosuke Ogura, A. Koenigsrainer, Jerzy W. Mozrzymas, S. Stefoni, M.L. Halperin, Margret Arnadottir, M. Dapporto, Satoru Tsunoda, Arie Oliven, V. Djordjević, I. Pejčić, William J. Kimberling, Gary E. Striker, M. Oh, Shuichi Hatakeyama, Hideaki Yamabe, M. Lago, Akira Noguchi, Tetsuo Shibata, Saime Paydas, Hiroshi Nihei, Sumalee Nimmannit, G. Devulder, Marian Klinger, Susumu Inaba, Touru Nishihara, L.A.H. Monnens, Hans Thysell, V. Stefanović, J.C. Boulanger, Ichiro Kajiwara, Akio Koyama, Jesús Montoliu, Panos Ziroyiannis, Stefan H. Jacobson, Sompong Ong-ajyooth, Manuel Martinez-Maldonado, and B. de Cagny
Subjects: Index (economics), business.industry, Statistics, Medicine, Subject (documents), business
Published: 1996

43. Surface properties and in vitro cytopathic effect of various strains of Trichomonas vaginalis

Author: A, González-Robles, M, Espinosa-Cantellano, C, Argüello, F, Anaya-Velázquez, A, Lázaro-Haller, and A, Martínez-Palomo
Subjects: Electrophoresis, Surface Properties, Virulence Factors, Cell Line, Electrophysiology, Mice, Species Specificity, Electric Impedance, Microscopy, Electron, Scanning, Trichomonas vaginalis, Animals, Humans, Female, Cell Surface Extensions, Trichomonas Vaginitis
Abstract: The in vitro cytopathic effect of four strains of Trichomonas vaginalis on cultured epithelial monolayers was analyzed through electrophysiology and electron microscopy. Interaction of trichomonads of two virulent strains (GT-10 and GT-13) with cultured MDCK cell monolayers mounted in Ussing chambers produced a rapid decrease in transepithelial resistance to less than 30% of control values after only 15 min. By 30 min the electrical resistance was practically abolished by the virulent parasites. In contrast, of two attenuated strains of trichomonads (GT-3 and GT-7) analyzed under similar conditions, GT-3 trophozoites required 180 min to reduce transepithelial resistance to 9% of control values, while monolayers in contact with GT-7 parasites still showed 28% of control values at this time of incubation. Sequential scanning electron microscopy confirmed the much faster and widespread cytopathic effect of virulent parasites. In contrast, the slow lytic process produced by attenuated trophozoites was reduced to focal areas of direct contact with epithelial cells. Another difference was found by measurement of the surface charge of the four strains of T. vaginalis by means of cell microelectrophoresis. While the two virulent strains showed a negative surface charge, the two attenuated strains had no detectable surface charge at neutral pH. When parasites were incubated with cationized ferritin and studied with transmission electron microscopy the surface of virulent trichomonads appeared heavily labeled, whereas the surface of attenuated parasites had only sparse and irregular ferritin binding.
Published: 2004

44. [Prevention of cardiovascular risk in renal transplantation. Consensus document]

Author: J M, Morales, M, González Molina, J M, Campistol, D, del Castillo, F, Anaya, F, Oppenheimer, J M, Gil Vernet, J M, Grinyo, L, Capdevila, I, Lampreave, F, Valdés, R, Marcén, F, Escuín, A, Andrés, M, Arias, and L, Pallardó
Subjects: Diabetes Complications, Alcohol Drinking, Arteriosclerosis, Cardiovascular Diseases, Risk Factors, Smoking, Fibrinogen, Humans, Obesity, Exercise, Homocysteine, Kidney Transplantation, Diet
Published: 2002

45. [Recovery of renal function in patients in a dialysis program]

Author: P, Rodríguez Benítez, F J, Gómez Campderá, M, Rengel, and F, Anaya
Subjects: Renal Dialysis, Humans, Kidney Failure, Chronic, Recovery of Function
Published: 2002

46. The Influence of Pre-Transplant Dialysis Modality On Patient and Graft Survival After Kidney Transplantation

Author: D. del Castillo, M. Arias, Roberto Marcén, A. Andrés, F. Anaya, Frederic Oppenheimer, Gainza F. de los Rios, Daniel Serón, and José M. Morales
Subjects: Transplantation, medicine.medical_specialty, Modality (human–computer interaction), business.industry, medicine.medical_treatment, medicine, Graft survival, business, medicine.disease, Dialysis, Kidney transplantation, Surgery
Published: 2014

47. [Incidence of diabetes mellitus and prevalence of type 1A diabetes mellitus in children younger than 16 years old from the province of Ciudad Real]

Author: P, Giralt Muiña, L, Santillana Ferrer, D, Madrigal Barchino, A, Merlo Garrido, B, Toledo De La Torre, and F, Anaya Barea
Subjects: Male, Diabetes Mellitus, Type 1, Adolescent, Spain, Child, Preschool, Incidence, Prevalence, Humans, Infant, Female, Child, Retrospective Studies
Abstract: Because of the lack of data from our province, we performed the present study to determine the current situation and future evolution in our region of the most frequent chronic disease in childhood.To evaluate the incidence of diabetes mellitus and the prevalence of type 1A diabetes mellitus in children younger than 16 years old from the province of Ciudad Real.We performed an epidemiological, cross-sectional, observational study. The mark-release-recapture method was used to calculate exhaustivity. The patients were selected through surveys to primary care centers, hospital registries and diabetics associations in our province. All type 1A diabetics were included in the calculation of prevalence. Only diabetics with onset of symptoms in 1999 were included in the calculation of incidence.The incidence of diabetes mellitus in children younger than 16 years old was 26 per 100,000. Twenty-three children were diagnosed with the disease, with an exhaustivity rate of 88.5 %. The prevalence of type 1A diabetes mellitus in children younger than 16 years old was 2.1 per 1,000 and 0.42 per 1,000 inhabitants. The prevalence in the general population was 0.88 per 1,000 inhabitants.The incidence of diabetes mellitus in children younger than 16 years old and the prevalence of type 1A diabetes mellitus in the province of Ciudad Real are higher than expected and are the highest of currently known rates in Spain.
Published: 2001

48. Angiotensin II type 1 (AT1) receptor antagonists in the treatment of hypertension after renal transplantation

Author: F. Anaya, Roberto Holgado, and Domingo Del Castillo
Subjects: medicine.medical_specialty, Mean arterial pressure, Urology, Renal function, Blood Pressure, Renal artery stenosis, Receptor, Angiotensin, Type 2, Losartan, Receptor, Angiotensin, Type 1, Angiotensin Receptor Antagonists, Postoperative Complications, Internal medicine, medicine, Humans, Antihypertensive Agents, Transplantation, Clinical Trials as Topic, Proteinuria, business.industry, medicine.disease, Angiotensin II, Kidney Transplantation, Endocrinology, Blood pressure, Nephrology, Hypertension, medicine.symptom, business, Kidney disease, medicine.drug
Abstract: Hypertension is highly prevalent after renal transplantation and has been associated with lower graft survival. Optimum management of post-transplant hypertension remains to be defined. Losartan, a potent, orally active and selective non-peptide blocker of the angiotensin subtype 1 receptor, could represent a useful drug for treating post-transplant hypertension. Recently, a prospective study of 12 weeks treatment with losartan has showed a satisfactory control of arterial hypertension associated with a decrease in proteinuria in this high-risk group of renal transplant patients. A retrospective study was performed to review the role of losartan as a renoprotective agent (evaluating blood pressure and proteinuria) in renal transplant recipients in a long-term follow-up. A total of 150 transplant recipients were included in the study. None of the patients had a serum creatinine > 3 mg/dl, or suspected renal artery stenosis, or other severe concomitant diseases. The indication for losartan therapy was hypertension, proteinuria and/or post-transplant erythrocytosis. The values of blood pressure, results of fasting haematology, blood chemistry and total proteinuria in 24-h urine samples were recorded at the time of initiation of losartan therapy, 6 and 3 months before the start, and at 3, 6, 12, 18 and 24 months thereafter. A tendency analysis by linear regression comparing two slopes before and after treatment was realized. A decrease in mean blood pressure and proteinuria, from 106.7 ± 0.9 to 98.2 ± 2.1 mmHg and from 1253.9 ± 188 to 91.2 ± 33.7 mg/24 h, P
Published: 2001

49. [Permanent neonatal diabetes associated with other anomalies]

Author: P, Giralt Muiña, J, Sánchez Del Pozo, F, Anaya Barea, M, García Silva, G, Lledó Valera, and A, Rosa García
Subjects: Diabetes Complications, Hypothyroidism, Infant, Newborn, Humans, Abnormalities, Multiple, Syndrome, Deafness
Abstract: Neonatal diabetes mellitus is defined as hyperglycemia detected in the first month of life of more than 2 weeks' duration, requiring insulin treatment. It is extremely uncommon (1/500,000 neonates) and is permanent in only 30% of cases. Several hypotheses concerning its etiology have been postulated, such as pancreatic immaturity, paternal uniparental isidisomy of chromosome 6, and the existence of a gene located in the 6 q 22-23 chromosome region subjected to imprinting and exclusively of paternal expression. The management of these patients is usually difficult. These neonates are underweight for their gestational age, and neither anti-insulin antibodies nor anti-islets are detected. We studied a neonate hospitalized because of low weight for his gestational age with dimorphic features and hyperglycemia since the 17 th day of life. Clinical and anatomical follow-up has been periodically performed to the present date. The child presents permanent neonatal diabetes with negative antibodies. Although various insulin patterns have been used since the onset of the syndrome, management remains difficult. The child presents hypothyroidism, bilateral neurosensory deafness, bilateral congenital cataract, myopia, dimorphic features, congenital stridor and slow weight-stature curve. The results of muscle biopsy and metabolic studies were normal. Wolfram's syndrome and mitochondrial diabetes were ruled out. This is an exceptional case of permanent neonatal diabetes associated with other malformations corresponding to no known syndromic patterns.
Published: 2001

50. Digestion of erythrocytes by Entamoeba histolytica. Correlative study with scanning electron microscopy and polyacrylamide gel electrophoresis

Author: J, Mora-Galindo, A, González-Robles, D, Alvarez, F J, Perea-Díaz, and F, Anaya-Velázquez
Subjects: Erythrocytes, Entamoeba histolytica, Microscopy, Electron, Scanning, Animals, Electrophoresis, Polyacrylamide Gel
Published: 2000

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

265 results on '"F. Anaya"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources